

SUMMARY STATEMENT:

GEMTUZUMAB ZOGAMICIN

**Recombinant Humanized Anti-CD33 Monoclonal Antibody (HP67.6 Antibody)-
Calicheamicin Drug Conjugate in Relapsed Acute Myelogenous Leukemia**

NDA 21-174

Table of Contents

1. General Information	4
1.1. Title/Heading - Medical Officer's Review	4
1.1.1. NDA # 21-174	4
1.1.2. M.O. Review #	4
1.1.3. Submission (date) October 29, 1999	4
1.1.4. Review completed (date)	4
1.1.5. Drug name CMA 676.....	4
1.1.6. Generic name gemtuzumab zogamycin.....	4
1.1.7. Proposed trade name: []	4
1.1.8. Chemical name (structure optional).....	4
1.2. Sponsor	4
1.3. Pharmacologic Category:.....	4
1.4. Dosage Form(s) and Route(s) of Administration.....	4
1.5. NDA Drug Classification.....	4
1.6. Important Related Drugs:.....	5
2. Material Reviewed.....	5
2.1. volume numbers which serve basis for this review).....	5
2.2. Other resources.....	5
3. Chemistry/Manufacturing Controls.....	5
4. Animal Pharmacology/Toxicology.....	5
5. Clinical Background	5
5.1. Proposed Indication	5
5.2. Treatment of AML.....	6
5.3. Administrative History	8
5.4. Relevant human experience.....	9
5.5. Related INDs and NDAs –	9
5.6. Foreign experience – see study # 202	9
5.7. Human Pharmacology, Pharmacokinetics, Pharmacodynamics: See PK review by Dr. Keiffer	9
6. Description of Clinical Data Sources.....	9
6.1. Patient Enumeration.....	9
6.2. Extent of Exposure	9
7. Clinical Studies	10
7.1. Phase 1 Trial:	10
7.2. Phase 2 trials: THE EFFICACY AND SAFETY OF GEMTUZUMAB ZOGAMICIN AS SINGLE AGENT TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST RELAPSE.....	15
7.2.1. Summary of clinical studies 201,202,203.....	15
7.3. Significant/Potentially Significant Events.....	40

7.3.1. Deaths.....	40
7.3.2. Other Serious Adverse events.....	41
7.4. Overview of Safety.....	42
7.4.1. Overdosage exposure.....	43
7.4.2. Drug-Demographic Interactions	43
7.4.3. Drug-Disease Interactions	44
7.4.4. Drug-Drug Interactions	44
7.4.5. Withdrawal Phenomena/Abuse Potential	44
7.4.6. Human Reproduction Data.....	44
8. Conclusions	44
9. Appendices	46
9.1. Appendix 1: Study Flow Chart:.....	46
9.2. Appendix 2: Proposed Labelling.....	48

INDEX OF TABLES

Table 1: Study Type and Design.....	9
Table 2: NUMBER (%) OF PATIENTS VS. NUMBER OF DOSES AT 9 mg/m ² GEMTUZUMAB ZOGAMICIN ^a	10
Table 3 : common observed infusion-related toxicities.....	12
Table 4: KEY INCLUSION AND EXCLUSION CRITERIA IN PHASE II STUDIES	17
Table 5: Number of subjects/patients.....	22
Table 6:Reasons for Non Enrollment	22
Table 7 : Demographic Data for Phase II studies	23
Table 8: FAB subtypes at initial presentation (M3 excluded).....	23
Table 9: Prognostic Characteristics at Relapse.....	24
Table 10: NUMBER (%) OF PATIENTS AND 95% CIs BY REMISSION CATEGORY IN PHASE II STUDIES	26
Table 11 : % PATIENTS WITH SECOND REMISSION vs DURATION OF FIRST REMISSION: RETROSPECTIVE REVIEWS WITH > 100 PATIENTS AND GEMTUZUMAB ZOGAMICIN IN PHASE II CLINICAL TRIALS	27
Table 12: RETROSPECTIVE REVIEWS WITH > 100 PATIENTS AND GEMTUZUMAB ZOGAMICIN PHASE II CLINICAL TRIALS: % PATIENTS WITH SECOND REMISSIONS.....	28
Table 13: SUMMARY OF PROGRESSION-FREE SURVIVAL ^a AND RELAPSE-FREE SURVIVAL ^b (201/202/203).....	29
Table 14:SUMMARY OF LANDMARK SURVIVAL (201/202/203)	30
Table 15: NUMBER (%) OF PATIENTS RECEIVING ADDITIONAL THERAPY AFTER GEMTUZUMAB ZOGAMICIN	30
Table 16: SUMMARY OF SURVIVAL AND TREATMENT OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS	31

Table 17: RELAPSE-FREE SURVIVAL	31
Table 18: OVERALL SURVIVAL AFTER HSCT (201/202/203)	32
Table 19:RESULTS OF MULTIVARIATE EXPLORATORY ANALYSIS FOR PROGNOSTIC FACTORS	32
Table 20: NUMBER (%) OF PATIENTS REPORTED TO HAVE THE MOST COMMON NCI GRADE 3 OR 4 SEVERITY INFUSION-RELATED TREATMENT-EMERGENT ADVERSE EVENTS BY DOSE ^a (STUDIES 201/202/203).....	34
Table 21: NO. PATIENTS (%) WHO DISCONTINUED FROM STUDY PART I – SUMMARY OF PRIMARY REASONS FOR DISCONTINUATION	34
Table 22:COMPARISON OF SAFETY RESULTS REPORTED IN LITERATURE ^a WITH RESULTS FOR PATIENTS WHO RECEIVED GEMTUZUMAB ZOGAMICIN.....	36
Table 23: NUMBER (%) OF PATIENTS WITH NON-HEMATOLOGIC LABORATORY TEST RESULTS OF CLINICAL IMPORTANCE IN PART 1 .	37
Table 24: NUMBER OF RED BLOOD CELL AND PLATELET TRANSFUSIONS ^a (STUDIES 201/202/203).....	38
Table 25: NUMBER (%) OF PATIENTS REPORTING ≥ 5% ^a BLEEDING TREATMENT-EMERGENT ADVERSE EVENTS IN PART I BY TREATMENT OUTCOME CATEGORY (STUDIES 201/202/203)	39
Table 26: SUMMARY OF DEATHS THAT OCCURRED IN PART I OF STUDIES 201/202/203	41
Table 27:PATIENTS EXPERIENCING SERIOUS AND UNEXPECTED ADVERSE EVENTS (STUDIES 201/202/203)	42
Table 28: NUMBER (%) OF PATIENTS BY REMISSION CATEGORYIN THE EFFICACY STUDIES	Error! Bookmark not defined.
Table 29: SUMMARY OF RELAPSE-FREE SURVIVAL FOR PATIENTS WITH CR AND CR _p IN THE EFFICACY STUDIES	Error! Bookmark not defined.

1. General Information

1.1. Title/Heading - Medical Officer's Review

1.1.1. NDA # 21-174

1.1.2. M.O. Review #

1.1.3. Submission (date) October 29, 1999

1.1.4. Review completed (date)

1.1.5. Drug name CMA 676

1.1.6. Generic name gemtuzumab zogamycin

1.1.7. Proposed trade name: []

1.1.8. Chemical name (structure optional)

P67.6-NAc-gamma calicheamicin DMH AcBut conjugate

1.2. Sponsor

Wyeth Ayerst

1.3. Pharmacologic Category:

immunoconjugate

1.4. Dosage Form(s) and Route(s) of Administration

Solution for intravenous injection

1.5. NDA Drug Classification

Standard

1.6. Important Related Drugs:

none

2. Material Reviewed

2.1. volume numbers which serve basis for this review)

NDA 21-174
Wyeth-Ayerst
Volumes 1,2 and 77-101

2.2. Other resources

Medline search of medical literature

Devita *et. al.*, Principles and Practice of Oncology,
5th Edition, New York, Lippincott 1997

3. Chemistry/Manufacturing Controls

See chemistry review by Dr. Chen

4. Animal Pharmacology/Toxicology

There is no previous clinical pharmacokinetic information for gemtuzumab zogamicin. Extrapolation of pharmacokinetic studies in animals is not thought to be predictive of clinical results because of the absence of CD33, which is presumed to be an important factor in elimination of the drug from plasma through binding and internalization into cells. However, a mass balance study of gemtuzumab zogamicin in rats showed that cumulative excretion after 336 hours post dose accounted for 72% of the radioactivity. Cumulative recoveries (percent of dose) were 12.6% and 58.6% for urine and feces, respectively. Single intravenous (IV) doses of 2.5, 25, and 75 µg/kg of calicheamicin in dogs resulted in concentrations that were below the limit of detection. At 250 µg/kg doses, calicheamicin concentrations fell below 2.5 ng/mL within 6 hours of dose administration. Similar low concentrations of calicheamicin were observed in rats after doses of 10, 100, and 300 µg/kg.

5. Clinical Background

5.1. Proposed Indication

5.2. Treatment of AML

Acute myeloid leukemia affects approximately 2.4 persons per 100,000 annually in the United States and occurs more commonly in adults than children, to a peak of 12.6 per 100,000 at age >65.¹ Chemotherapy is highly toxic, with a mortality rate of 3-30%, and requires 7 days of inpatient continuous infusion. Response rates for de novo AML are generally above 50% depending on prognostic characteristics, however most patients eventually relapse. Long-term survival is < 20% in all AML patients treated with chemotherapy and is somewhat better in a select subset of patients with good prognostic characteristics who are able to tolerate intensive postremission therapy.

The CD33 antigen is a 67 kd glycoprotein that functions as a sialic acid-dependent adhesion protein.² CD33 is expressed on leukemic myeloid colony-forming cells (CFC) and on about 90% of AML myeloblasts, including leukemic clonogenic precursors; however, it is not expressed on pluripotent hematopoietic stem cells and is absent from nonhematopoietic tissue.³ *In vitro* studies showed rapid internalization of the antibody by the target cell. These properties make it possible to use antibodies against CD33 to specifically deliver agents to leukemia cells.⁴

Antibody therapy is ideally suited to treatment of hematologic malignancies because of the ready accessibility of neoplastic cells in the circulation. Monoclonal antibodies (MoAb's) have been manufactured against the CD33 epitope. Clinical studies have shown that radiolabeled anti-CD33 murine MoAbs localize to the bone marrow of patients with AML.⁵ Three basic approaches have been used in the therapeutic use of monoclonal antibodies in hematologic malignancy.⁶ In the first approach, the antibodies alone have been used to elicit an immune response to the malignant clone. Initial *in vivo* studies with an unmodified murine anti-CD33 antibody in patients with AML demonstrated that the antibody quickly bound to leukemia cells and that the antigen-antibody complex rapidly internalized following cell

¹ Lowenberg B et.al: Acute Myeloid Leukemia, *New England Journal of Medicine*, 341:14, 1051-1061, 1999.

² Andrews RG, Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. *Blood* 62:124, 1983.

³ Dinndorf PA, et.al.: Expression of normal myeloid-associated antigens by acute leukemia cells. *Blood* 67:1048, 1986

⁴ Bernstein ID et. al: Treatment of acute myeloid leukemia cells *in vitro* with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. *J Clin Invest* 79:1153, 1987

⁵ Van der Jagt RH, et. al: Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xeno-graft tumor model. *Cancer Res* 52:89, 1992

⁶ Appelbaum FR: Antibody-targeted therapy for myeloid leukemia. *Semin Hematol* 1999 Oct;36(4 Suppl 6):2-8

binding. However, when administered to patients with overt leukemia, unmodified antibody resulted in only brief decreases in peripheral blast counts, not in sustained response.⁷

Radiolabeled antibodies have been explored as a stand-alone treatment or in the context of bone marrow transplantation.⁸ In an effort to avoid toxicities to normal stem cells residing alongside leukemic cells in the marrow, studies have been performed to explore the use of ²¹³Bi conjugated to an anti-CD33 monoclonal antibody. The short path length of this alpha-emitter could theoretically allow killing of the targeted leukemic cell without damage to normal neighbors. Of 12 patients with recurrent AML who received this drug, eight had reductions in marrow and peripheral blast counts. Complete remissions (CRs) have not been observed to date.

The third approach involved conjugating a toxin to the CD33 antibody, and this was the technique used in this study, in which a recombinant humanized anti-CD33 MoAb was linked to NAc-gamma calicheamicin (NAc-cal) and given to patients with relapsed AML.⁹ The calicheamicins, small molecules with weights of approximately 1.5 kd, are potent antitumor antibiotics that were initially identified by their ability to damage DNA in screening tests.¹⁰ They bind DNA in the minor groove and produce site-specific double strand break. They contain two "domains": the enediyne portion, which, on reductive activation, is responsible for DNA cleavage, and the aryltetrasaccharide tail, which anchors the whole molecule to the DNA minor groove. The aryltetrasaccharide moiety can efficiently inhibit the binding of transcription factors to a target DNA containing TCCT, generally considered to be the preferred canonical calicheamicin binding sequence. In this way, the drug can specifically interfere with DNA-related biological processes such as transcription and other biological events that depend on protein-DNA interactions. Calicheamicin can interfere with biological processes not simply by cleaving free DNA but also by displacing a DNA-binding protein through competition or modulation of DNA structure, according to recent research.¹¹ The antibody-calicheamicin complex is internalized, and it is believed that calicheamicin is cleaved from the gemtuzumab zogamicin molecule within the cell. Some calicheamicin then binds to DNA, causing cell death. Studies in animals have demonstrated that unconjugated calicheamicin derivatives represent less than 4% of total derivatives in plasma, suggesting that calicheamicin remains linked to gemtuzumab zogamicin in serum.¹²

⁷ Scheinberg DA: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. *J Clin Oncol* 9:478, 1991

⁸ . Appelbaum FR: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. *Transplantation* 54:829, 1992

⁹ Sievers EL; Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate, *Blood* 1999 Jun 1;93(11):3678-84

¹⁰ Zein N, Sinha AM, McGahren WJ, Ellestad GA: Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. *Science* 240:1198, 1988

¹¹ Sissi C, et.al. Interaction of calicheamicin and its related carbohydrates with DNA-protein complexes, *PNAS*, Vol. 96, Issue 19, 10643-10648, September 14, 1999

¹² Wyeth-Ayerst Laboratories, NDA 21-174, Volume 103 p. 99

5.3. Administrative History

Original IND No. [] for gemtuzumab zogamicin was submitted on November 9, 1994 to the Division of Oncology Drug Products. The development of gemtuzumab zogamicin was facilitated by the highly interactive relationship of the FDA and Wyeth-Ayerst. A number of meetings and teleconferences were held in which key aspects of the development program were discussed. The most significant of these interactions are summarized below:

An End-of-Phase I meeting was held on January 14, 1997. Sponsor's plan to support an NDA filing with one pivotal safety and efficacy study (Protocol 201) in 55 patients was deemed to be generally acceptable, assuming favorable results.

As a follow-up to the End-of-Phase I meeting, a teleconference was held on July 25, 1997 at the request of Wyeth-Ayerst to confirm the Division's acceptance of revisions to the pivotal 201 study relative to length of follow-up and the ability to measure the duration of gemtuzumab zogamicin response. The Division acknowledged the difficulties in standardizing post remission therapy and establishing an appropriate length of follow-up in relapsed AML patients prior to additional therapy such as bone marrow transplantation. The Division agreed that the revisions to the protocol were acceptable and had addressed their concerns.

A meeting to discuss the interim analysis results from the pivotal 201-US study was held on September 16, 1998. The Division noted that morphologic remissions (MRs) could be used to support the primary complete remission (CR) endpoint if it was demonstrated in the NDA that MRs were functionally and clinically similar to CRs.

A Pre-NDA meeting specific to clinical issues was held on May 12, 1999. The Division agreed that the overall content and format of the NDA were acceptable. The Division also agreed that the patient numbers (104 patients in Phase 2) and data collection appeared sufficient for an NDA filing. The Division indicated that the proposal to include 28 day follow-up data on all 104 Phase H patients, and 6-month follow-up on 55 of the 104 Phase 2 patients, in the initial NDA submission was acceptable.

The Division also noted that Wyeth-Ayerst would need to clearly demonstrate the clinical benefit of the new response category of morphologic remission (MR) in order for MR to be used to support the primary endpoint of CR. The Division suggested that Wyeth-Ayerst use historical controls in the NDA as a comparison to support safety and efficacy claims in the NDA.

A Pre-NDA meeting specific to chemistry issues was held on June 2, 1999. The Division concurred with the proposal to designate [] for the production of gemtuzumab zogamicin. The Division also agreed with Wyeth-Ayerst's

proposal to designate the bulk liquid conjugate as the active drug substance and lyophilized gemtuzumab zogamicin as the drug product.

The amount of stability data to be included in the initial filing was agreed to by the Division. Because gemtuzumab zogamicin is intended to treat a seriously ill population, and based on the biotechnology products guideline, the Division indicated that they would be flexible with respect to filing the NDA with less than 12 months real-time drug product stability data. The amount of stability data to be included in the original NDA was also outlined in a position paper submitted on September 15, 1999 (Serial No. 190).

5.4. Relevant human experience

See clinical studies section

5.5. Related INDs and NDAs –

none

5.6. Foreign experience – see study # 202

5.7. Human Pharmacology, Pharmacokinetics, Pharmacodynamics: See PK review by Dr. Keiffer

6. Description of Clinical Data Sources

6.1. Patient Enumeration

Table 1: Study Type and Design

Protocol #	Design	Accrual	Location(s)	Dates	Comments
0903A1-101	Phase I open label dose escalation	41	Seattle, WA Duarte, CA	4/95-5/98	MTD = 9 mg/m ²
0903A1-201	Phase II open label	59	Multicenter US/CA	5/97-ongoing	Pivotal trial
0903B1-202	Phase II open label	25	Multicenter Europe	4/98-ongoing	Relapse post BMT allowed
0903B1-203	Phase II open label	20	Multicenter US/Europe	12/97-ongoing	Elderly Pts
0903A1-102	Phase I	11	US	ongoing	Pediatric

6.2. Extent of Exposure

41 patients (including the patient who was enrolled and treated twice) received at least 1 dose of gemtuzumab zogamicin ranging from 0.25 to 9 mg/m². Table 4 presents the numbers of patients receiving 1, 2, or 3 doses of gemtuzumab zogamicin by dose group. For the 88 patients who received 2 or 3 doses, the number of days between the first and second dose ranged from 13 to 29 days, with a median of 16 days. The mean (+/- SD) number of days between the first and second dose was 17.9 (+/- 4.4).

Table 2: NUMBER (%) OF PATIENTS VS. NUMBER OF DOSES AT 9 mg/m² GEMTUZUMAB ZOGAMICIN^a

	Study 101	Studies 201/202/203
Total Doses	(n = 7)	(n = 104)
1	3 (43)	16 (15)
2	2 (29)	85 (82)
3	2 (29)	3 (3)

7. Clinical Studies

7.1. Phase 1 Trial:

7.1.1.1. Trial # 0903 A1 101

7.1.1.2. TITLE: A PHASE I STUDY OF RECOMBINANT ANTI-CD33 MONOCLONAL ANTIBODY (hP67.6 ANTIBODY)-CALICHEAMICIN DRUG CONJUGATE (hP67.6 CONJUGATE) AS TREATMENT FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

7.1.1.3. Objective/Rationale

1. To study the safety of gemtuzumab zogamicin in terms of:
 - Acute infusion related toxicities (ie, occurring within 6 hours of the start of the infusion of test drug).
 - Hematologic toxicities.
 - Nonhematologic toxicities.
2. To define the maximum tolerated dose (MTD) of gemtuzumab zogamicin.
3. To study the pharmacokinetic properties of gemtuzumab zogamicin.

7.1.1.4. Design

This trial was an open-label, single-arm, phase I dose escalation study to examine the effects of gemtuzumab zogamicin given to patients with CD33-positive AML. It was conducted at two institutions in the United States.

7.1.1.5. Protocol

7.1.1.5.1. Population:

Men and women aged 16 to 70 years with CD33 positive (+) acute myeloid leukemia (AML) were eligible for entry in the study if they had failed to achieve remission or they had a relapse after remission. Patients with a relapse who had undergone marrow transplantation and in whom the transplant had engrafted were also eligible. Forty (40) patients in 8 treatment groups were enrolled at the 2 investigational sites. Twenty-one (21) men and 20 women were enrolled. The mean age was 48.6 years. All patients had AML, and 22 (54%) had previously undergone a bone marrow transplant. Two (2) patients had a history of myelodysplastic syndrome.

7.1.1.5.2. Treatments:

Originally, 5 treatment groups were planned with 3 to a maximum of 6 patients each, at dose levels of 0.25, 0.5, 1, 2, and 4 mg/m² (expressed as dose of protein equivalent). In an attempt to reach the MTD, 3 additional treatment groups (5, 6, and 9 mg/m²) were added during the conduct of the study. Patients received study drug as a single 2-hour IV infusion per dose for a maximum of 3 doses, with a minimum of 14 days between doses.

7.1.1.5.3. Safety endpoints:

Adverse events and toxicities were summarized by treatment group in 3 categories as follows:

- a) acute and delayed infusion-related toxicities,
- b) hematologic toxicities, and
- c) nonhematologic toxicities.

7.1.1.5.4. Safety results:

This ascending dose trial in patients with relapsed and refractory AML evaluated the safety of dose levels of gemtuzumab zogamicin from 0.25 to 9 mg/m². In addition to 7 patients who died within 30 days of receiving gemtuzumab zogamicin (section 10.4.1), and 3

who were withdrawn for reasons related to safety (section 10.4.3), there were 39 hospitalizations or other serious adverse events reported.

Hospitalizations: The majority (21/28; 75%) of the hospitalizations were for fever and/or neutropenia. One patient died with marrow aplasia after 3 doses of CMA-676 at 6 mg/m². In subsequent studies, > 15% cellularity on bone marrow biopsy was required before the administration of a third dose of gemtuzumab zogamicin to prevent prolonged myelosuppression. The most common acute infusion-related clinical adverse event was a postinfusion symptom complex consisting of fever and chills. This symptom complex generally occurred within 6 hours of the start of the gemtuzumab zogamicin infusion and tended to be less frequent and less severe with subsequent doses. The most common delayed infusion-related events over all dose periods combined were fever (reported by 44% of patients), nausea (32%), chills (27%), leukopenia (22%), vomiting (12%), rash (12%), pain (10%), and thrombocytopenia. Nausea, vomiting, leukopenia, thrombocytopenia, and rash tended to occur more frequently at the higher dose levels.

Table 3 : common observed infusion-related toxicities

Adverse Event	ACUTE (6-HOUR)			DELAYED (24-HOUR)		
	GZ Treatment Group (mg/m ²)					
	5 (n = 6)	6 (n = 8)	9 (n = 7)	5 (n = 6)	6 (n = 8)	9 (n = 7)
Any adverse event	6 (100)	5 (63)	4 (57)	6 (100)	6 (75)	7 (100)
Fever	4 (67)	4 (50)	3 (43)	4 (67)	2 (25)	4 (57)
Nausea	2 (33)	2 (25)	1 (14)	2 (33)	2 (25)	6 (86)
Chills	5 (83)	4 (50)	4 (57)	2 (33)	0	4 (57)
Leukopenia	-	-	-	3 (50)	2 (25)	1 (14)
Vomiting	2 (33)	0	1 (14)	1 (17)	2 (25)	2 (29)
Rash	-	-	-	3 (50)	1 (13)	1 (14)
Hypotension	1 (17)	1 (13)	1 (14)	-	-	-
Thrombocytopenia	-	-	-	0	2 (25)	0

Antibodies: Two patients exhibited evidence of development of antibodies to the calicheamicin -linker complex. One patient, after receiving 3 doses of gemtuzumab zogamicin (1 mg/m²), had a complete remission for 5½ months and was eligible for a second course of gemtuzumab zogamicin after bone marrow relapse occurred. He received a second course of gemtuzumab zogamicin in the 6 mg/m² treatment group. Approximately 5 minutes after the second dose of gemtuzumab zogamicin was administered, the patient experienced mild shortness of breath and chest tightness lasting no more than 10 minutes. Treatment consisted of the administration of oxygen for a short period. Immune response studies documented a significant rise in titers of antibody to the calicheamicin linker complex. Thus, this patient appears to have had a respiratory syndrome associated with immune reaction to the gemtuzumab zogamicin conjugate. One other patient developed antibodies to

the calicheamicin-linker complex after a third dose of gemtuzumab zogamicin, with no accompanying clinical signs reported.

Neutropenia: The duration of neutropenia may be related to dose level. Two (2) patients in this study had CR. One patient, who had CR in the 1 mg/m² dose group, had neutrophil count recovery to > 1,500/μL 4 days after receiving the third dose of gemtuzumab zogamicin. Another patient, who had CR in the 4 mg/m² treatment group, had neutrophil count recovery to > 1,500/μL 35 days after receiving the third dose of gemtuzumab zogamicin. These data, though scant, suggest a relationship between dose level and the duration of neutropenia. Prolonged neutropenia was observed in 2 patients. One (1) patient who received 3 doses of gemtuzumab zogamicin at 9 mg/m² experienced grade 4 neutropenia for 6 weeks after the third dose was administered. An additional patient who received 2 doses of gemtuzumab zogamicin at 9 mg/m² developed sepsis, confirmed by blood culture, while neutropenic, and experienced grade 4 neutropenia and thrombocytopenia after that dose for a total of 7 weeks before dying from infection.

Thrombocytopenia: 10/40 patients were observed to exhibit grade 4 thrombocytopenia. 3 patients had thrombocytopenia at baseline. The duration of thrombocytopenia was several weeks, and was complicated by the presence of residual leukemia in some patients. The identification of several patients with blast clearance and persistent thrombocytopenia suggested that gemtuzumab zogamicin is particularly toxic to megakaryocytes, and led to the proposal of a category of ‘morphologic remission’ with clearance of blasts but incomplete recovery of platelets.

Transaminases: 2 patients had grade 4 elevations of transaminases, and 9 patients had grade 3 elevations of transaminases. Most of these abnormalities were ascribed to concomitant medications and progression of disease.

Conclusions: Initially the MTD was not reached because drug-related events were often difficult to distinguish from disease-related events. The duration of myelosuppression encountered in 2 patients at 9 mg/m² was considered clinically important. 9 mg/m² of gemtuzumab zogamicin was therefore chosen to be the appropriate safe dose for phase II clinical trials. Administration of more than two doses of CMA-676 may be associated with prolonged myelosuppression and possibly an increased risk of the development of antibodies to the linker complex.

7.1.1.6. Efficacy endpoint outcomes

Response rates: Two (2) of the 41 patient treatments resulted in objective CRs after 3 doses of CMA-676, one treated at 1mg/M² and one at 4 mg/M². 7 additional patients treated with doses of 5, 6, and 9 mg/M² had clearance of leukemic blasts (<5%) from their blood and bone marrow without full recovery of peripheral counts. The term “morphologic remission” was adopted to describe the finding that some of the patients in this study had

clearance of blast cells with incomplete platelet recovery. Because of the findings from study 101, MR was included in the phase II protocols as a secondary efficacy endpoint. Originally, MR was defined as clearance of leukemia from marrow, but after discussions with regulatory agencies, a more specific definition of MR was developed for the phase II protocols. MR was defined exactly the same as CR for all the parameters except platelets. To be classified as having a MR, patients had to meet all the criteria for CR except recovery to 100,000 platelets/ μ L. The MR patients had to have sufficient bone marrow recovery to be platelet transfusion independent.

Pharmacodynamics: Although evidence of efficacy was obtained at dose levels below 9 mg/m², at 9 mg/m² a high rate (4/7) of patients had blast clearance from the bone marrow. In addition, evaluation of the CD33 saturation data led to the conclusion that a dose level of 9 mg/m² would be effective in saturating CD33 sites in all patients regardless of leukemia burden. It is believed that gemtuzumab zogamicin exerts its antineoplastic effect by binding to CD33 positive cells and then being internalized. Extensive saturation of CD33 binding sites is thus fundamental to effective therapy. In study 101, CD33 saturation was evaluated with doses of gemtuzumab zogamicin ranging from 0.25 to 9 mg/m². Peripheral blood samples were collected at baseline, 3, and 6 hours after the gemtuzumab zogamicin infusion began and were analyzed to determine the percentage of CD33 sites on mononuclear cells that were saturated by gemtuzumab zogamicin. There was variability in saturation when the area under the concentration time curve (AUC) was less than 100 mg h/L. CD33 site saturation increased with dose level. Patients who had experienced CRs or clearance of blasts all had maximum saturation of 70% and above during the first 6 hours after administration of the first dose of gemtuzumab zogamicin. These data support the conclusion that one prerequisite for clinical response is the delivery of a sufficient dose of calicheamicin to the leukemic cells. These data also support the conclusion that a dose of 9 mg/m² of gemtuzumab zogamicin can saturate CD33 sites.

Pharmacokinetics: Blood samples were collected throughout the 96-hour sampling period that followed initiation of gemtuzumab zogamicin infusion. Only a limited assessment of the pharmacokinetic parameters in the lower- or higher-dose treatment groups could be made because of the limits of quantitation or because the sampling period was smaller than 3 times the estimated t_{1/2}. There was no consistent accumulation between dose periods for any of the dose groups. In general, concentrations increased as gemtuzumab zogamicin doses were escalated, but a definitive assessment of dose linearity could not be made because of the large inter-subject variability and the small numbers of patients in the treatment groups. The half life of the hP67.6 antibody was 69+/- 37 hours.

7.1.1.7. Conclusions of 101 study

Gemtuzumab zogamicin administered as a single agent to patients with relapsed or refractory AML at dose levels of up to 9 mg/m² caused significant myelosuppression. Seven patients died within 30 days of study drug administration, six of these deaths were attributed to the disease progression and one to sepsis secondary to prolonged myelosuppression. Greater than two doses resulted in prolonged myelosuppression in two patients. Safety data suggested 9mg/M² as the MTD, and CD33 receptor site saturation data further supported the choice of 9mg/M² as the appropriate dose for phase II studies. 7 patients had clearance of blasts and 2 patients had complete remissions at doses \leq 9mg/M².

Two patients developed antibodies to the calicheamicin-linker complex, one with clinical symptoms. Remission was observed in two patients. The results of this study provided the safety and preliminary efficacy data to initiate phase II trials at a dose of 9 mg/m². The dosing interval of 14 days was based on the half-life of the antibody. A dose would be expected to be cleared from the body in 4 to 5 half lives, or approximately 12 to 15 days. Weekly administration might result in accumulation, whereas monthly administration might result in disease recurrence

7.2. Phase 2 trials: THE EFFICACY AND SAFETY OF GEMTUZUMAB ZOGAMICIN AS SINGLE AGENT TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST RELAPSE

7.2.1. Summary of clinical studies 201,202,203

Primary data from three phase II clinical studies was submitted in this NDA, which included 13 sites in the US, 2 in Canada, and 17 in Europe. A total of 154 patients were screened and 104 enrolled.

Reviewer comment: The submission of phase II studies rather than randomized controlled trials was agreed to by the FDA because the rarity of the disease would significantly limit accrual to a multi-arm trial.

7.2.1.1. Objective/Rationale

7.2.1.1.1. Primary:

- To assess efficacy in terms of the number of patients with acute myeloid leukemia (AML) who attained a complete remission (CR);
- to assess the safety of gemtuzumab zogamicin.

7.2.1.1.2. Secondary:

- To assess the duration of CRs and morphologic remissions (MRs);
- To assess the pharmacokinetic (PK) properties of gemtuzumab zogamicin;
- To assess possible predictors of response to gemtuzumab zogamicin.

7.2.1.2. Design/ Methodology:

These were 3-part, open-label, single-arm, multidose studies.

7.2.1.3. Institutions

Patients were enrolled at 13 investigational sites in the United States and Canada and 17 sites in Europe as of 31 Dec 1998

7.2.1.4. Protocol

7.2.1.4.1. Population, procedures

Main criteria for inclusion: Patients with CD33 positive AML in first relapse after at least 6 months of CR (3 months in study 203). Patients were required to have >5% blast cells identifiable by flow cytometry, of which a high percentage expressed CD33. For eligibility, CR was defined as the date bone marrow biopsies or aspirate specimens showed clearance of leukemic blasts. ≥ 3 months of CR was allowed in study 203.

Exclusion: Patients with secondary leukemia, FAB M3 promyelocytic leukemia, previous MDS, or history of prior chemotherapy for relapse were excluded. Patients with a history of previous hematopoietic stem cell transplant were allowed only in study 202.

Table 4: KEY INCLUSION AND EXCLUSION CRITERIA IN PHASE II STUDIES

Criteria	Study 201	Study 202	Study 203
Patients with AML in first relapse	Required	Required	Required
CD33-positive phenotype	Required	Required	Required
Minimum age, years	18	18	60
Duration of first remission, months	6	6	3
Prior HSCT	Not permitted	Permitted ^a	Not permitted
Baseline serum creatinine	≤ 2.0 mg/dL	≤ 2.0 mg/dL	≤ 3.0 mg/dL
Baseline serum total bilirubin	≤ 1.5 mg/dL	≤ 1.5 mg/dL	≤ 2.0 mg/dL

a. Originally not permitted, but protocol 202 was amended to allow HSCT.

7.2.1.5. Methodology:

See Appendix 1 for study flow chart

7.2.1.5.1. Prestudy Screening

All patients were screened within 1 week before administration of the first dose:

At screening, within 1 week before dose administration, the following were performed:

- Medical history - including history of past and present illness; full history of the course of AML with response to prior therapy, noting cytogenetic and molecular markers (if information is available) and current medical problems.
- Complete physical examination - including demographics (sex, birth date, ethnic origin), a physical examination with a review of systems, assessment of performance status, vital signs (sitting blood pressure, pulse, respiratory rate, and oral temperature), height and weight.
- Laboratory evaluation - including CBC with differential, blood chemistry, prothrombin time (PT) and partial thromboplastin time (PTT).Chest x-ray film - Posteroanterior and lateral.Electrocardiogram (ECG) - including rate, rhythm, complex and interval abnormalities, and other relevant abnormal findings. Beta-human chorionic gonadotropin - serum pregnancy test - for women of childbearing potential. Urinalysis – including specific gravity, pH, assessment of

protein/albumin, glucose/sugar, ketones/acetone, hemoglobin/blood, microscopic examination

- Bone marrow aspirate and biopsy, and histochemical stains (myeloperoxidase, nonspecific esterase, and periodic acid Schiff stains). Immunophenotyping and confirmation of CD33+ AML/patient eligibility. Wright-Giemsa stained slides for morphologic evaluation of bone marrow aspirate (2 slides per specimen) for review by an independent consultant for confirmation of AML. This was done in a blinded fashion.

All studies were conducted on an outpatient basis with an initial study drug infusion observation period for each patient. Gemtuzumab zogamicin (5 mg/vial); 9 mg/m² was administered as a single 2-hour intravenous (IV) infusion on day 1. The observation period began with the start of each infusion and continued for 8 hours during dose period 1. The infusion observation period was 6 hours for subsequent dose periods as long as no clinically significant infusion-related events occurred during dose period 1. In part I, (dose administration and evaluation) patients were eligible to receive a subsequent dose at least 14 days (but less than 28 days) from the previous infusion, if the following conditions were met:

1. The patient had recovered from reversible non hematologic toxicities resulting from the first cycle,
2. There was no evidence of uncontrolled infection
3. There was no evidence of disease progression,
4. There was no evidence of antibody formation .

Investigators could delay the next dose beyond 14 days to allow the patient to recover from serious infections or other medically serious events. Delay beyond 28 days was not allowed because of concern that this interval would allow regrowth of leukemia cells, and extend the overall period of neutropenia experienced by patients.

Withdrawal from study: patients were withdrawn from the study if they were non evaluable or failed to show up for followup, and for disease progression, production of antibodies, and for serious adverse events.

Concomitant treatment:

All patients were premedicated with acetaminophen 650-1000g and benedryl 50 mg to decrease acute infusion-related symptoms.

Hydroxyurea 2g/day was administered to patients with white counts above 30,000 to decrease the likelihood of tumor lysis syndrome. This was discontinued 24 hours prior to treatment. Other cytotoxics and immunosuppressives were not allowed on protocol.

Growth factors and cytokines were not allowed. All other clinically indicated medications were allowed. Use of prophylactic antibiotics was not specified in the protocol.

Duration of treatment:

- Study part I - approximately 50 days (7 days screening; 2 doses with >14 and < 28 days between doses; 28-day follow-up after the last dose). Selected patients received an additional dose and follow-up dose period for a total of approximately 64 days in study part I.
- Study part II - approximately 6 months additional follow-up.
- Poststudy part III (patients completing study part II) - additional follow-up by telephone call every 3 months for 18 months; then patients were followed every 6 months until death.

Significant protocol amendments:

A total of 12 amendments were made to the 3 studies. The most significant amendments specified pretreatment medication to prevent infusion-related symptoms, allowed increased accrual, and allowed retreatment for subsequent relapse.

Initially a third dose of CMA 676 was allowed in patients who had not achieved a response after 2 doses, however, only 2 patients were treated with the extra dose and this option was discontinued due to prolonged myelosuppression and lack of efficacy. Study 202 was amended to allow prior hematopoietic stem cell transplant (HSCT).

7.2.1.5.2. Endpoints and objectives

The primary objectives of each study were

1. To assess efficacy in terms of the number of patients attaining CR.
2. To assess the safety of gemtuzumab zogamicin.

The secondary objectives were

1. To assess the duration of CRs and MRs.
2. To assess the PK properties of gemtuzumab zogamicin.

3. To assess possible predictors of response to gemtuzumab zogamicin.

In addition, data were collected and presented regarding overall survival, health outcomes assessments, hematologic characteristics of response, and post-gemtuzumab zogamicin treatments.

Criteria for evaluation/Efficacy assessment methods:

Study part I - primary endpoint: **CR** defined as

- a) leukemic blasts absent from peripheral blood;
- b) percentage of blasts in the bone marrow $\leq 5\%$;
- c) peripheral levels of hemoglobin ≥ 9 g/dL, platelets $\geq 100,000/\mu\text{L}$, absolute neutrophil count $\geq 1500/\mu\text{L}$; and
- d) the patient being red blood cell and platelet-transfusion independent.
- e) The definition for **MR** was the same as that for CR except that platelets were not required to reach $100,000/\mu\text{L}$. Patients who had no leukemic blasts in the peripheral blood and $\leq 5\%$ blasts in bone marrow (measured by bone marrow aspirate or biopsy) at the end of part I visit but did not meet other criteria for CR or MR were eligible to achieve CR or MR status during part II.

Study part II - secondary endpoint: duration of CR and MR were evaluated in part II for approximately 6 months. All patients were followed in poststudy part III regardless of remission/relapse status at the end of study part II

Safety assessment methods:

Part I: physical examination, assessment of performance status, vital signs and possible drug-related toxicities, laboratory evaluations, chest X-ray film, electrocardiogram, and antibodies against calicheamicin and against the hP67.6 conjugate. Adverse events were assessed at each visit.

Part II: monthly interim physical examination, assessment of vital signs, performance status, status of disease, and monthly complete blood count with differential for patients who were CR or MR or who did not meet all the criteria for CR or MR, but had $< 5\%$ bone marrow blasts at the end of part I. Other patients had only status of disease evaluated monthly during part II. Part III: overall patient status (duration of remission and survival).

Pharmacokinetic assessment methods: Plasma samples were to be collected at hour 0 (before dose administration) and 1, 2, 3, 4, and 6 hours after dose administration on each day of study drug administration, and then on days 3, 8 and 10 following each drug administration. A final sample was to be collected on day 28 of the last dose period. Plasma samples were assayed for hP67.6, unconjugated calicheamicin, and total

calicheamicin. The PK parameters were assessed by using noncompartmental analysis methods for each dose period for every patient. The PK parameters included maximal or peak plasma or serum drug concentration (C_{max}), time to reach observed C_{max} (t_{max}) half-life associated with the terminal slope ($t_{1/2}$), terminal slope (λ_z) and area under the concentration time curve (AUC). In addition to these parameters, the AUC ratios of calicheamicin, both total and unconjugated, to hP67.6 was calculated. The PK parameters were summarized for each assayed species [hP67.6, unconjugated calicheamicin, and total calicheamicin] by dose period, and a statistical comparison was performed across the first and second dose periods.

7.2.1.5.3. Statistical considerations

Statistical methods: The study design used was a modification of the Simon Two-Stage Design. Sample size requirements and stopping rules were based only on the complete remission rate and did not consider morphologic remission rate, safety profile of the test article etc. For this reason, the decision to continue the study beyond the interim analysis was not based solely on the complete remission rate, but rather resulted from an evaluation of the composite efficacy and safety information available at the time of the interim analysis. The results of the first stage of the Simon Two-Stage Design served only as a guide to this decision making process. The statistical section of the protocol has been amended to clarify how the Simon Two-Stage Design was modified and used for this project.

Reviewer comment: the decision to continue the study was based on 2 CR's and 1 MR – by strict criteria of the CR being the primary endpoint, the study should have been terminated. The accrual for studies 201 and 203 was extended for unspecified reasons.

7.2.1.6. Results

7.2.1.6.1. Patient Disposition, comparability

Study 201 was a 3-part, open-label, single-arm, multidose study with patients enrolled at 11 investigational sites in the United States and Canada as of 31 Dec 1998. This study planned: a sufficient number of patients to allow for the assessment of 55 evaluable patients. Enrollment extended to an additional 55 patients by Amendment IV. Enrolled (as of 31 Dec 1998): 59; completed part I: 59; analyzed: 59 in this interim study report (data cutoff date 15 Mar 1999). The study remains open for enrollment, and final results will be summarized in a subsequent report.

Study 202 was similar in design except that prior BMT was allowed and was conducted at 17 sites in Europe. This study planned to allow for the evaluation of approximately 20 patients. For this interim report, 38 were screened; 25 were enrolled and

1 of these patients was treated with a second course of gemtuzumab zogamicin for a total of 26 patient treatments. Twenty-three (23) completed the study and all 25 patients were included in the safety and efficacy analyses. Amendment IV of the protocol allowed for the enrollment of up to 150 patients and enrollment in the study is ongoing.

Study 203 was designed to determine efficacy in patients over 60 years old, and was carried out at 4 and 8 sites in the United States and Europe, respectively. This study planned: a sufficient number of patients to allow for the assessment of 55 evaluable patients. Enrolled (as of 31 Dec 1998): 20. One (1) of the patients was given a second course of gemtuzumab zogamicin. Completed: 20. Analyzed: 20. Enrollment is ongoing.

Table 5: Number of subjects/patients

Study	Planned	Enrolled	Screened	Status	Maximum*
201	55	59*	88	open	110
202	20	25*	38	open	150
203	55	20	28	open	55

*enrollment increased by protocol amendment

The primary reason for screened patients not to be enrolled was insufficient expression of CD33 by flow cytometry. Other common reasons for exclusion were misdiagnosis (ALL), review of pathological materials revealing the patients were not in relapse, and rapid progression of the disease:

Table 6: Reasons for Non Enrollment

Study	Not enrolled	Dim CD 33	Misdiagnosis	Other
201	29	14	3	12
202	18	10	1	7
203	8	4	3	1
Total	55	28	11	16

7.2.1.7. Demographics

A total of 104 patients were enrolled, 58% male, 92% Caucasian, with an age range of 22-84 and a mean age of 57. Protocol 203 had a higher mean age of 70 years (Table 7):

Table 7 : Demographic Data for Phase II studies

<i>Study</i>	<i>#</i>	<i>Male</i>	<i>Female</i>	<i>Race-white</i>	<i>Mean age</i>	<i>SD</i>	<i>Range</i>
201	59	30	29	54	52.7	15.8	22-81
202	25	18	7	24	57.4	12.1	30-79
203	20	12	8	18	70	7	60-84
All	104	60	44	96	57.1	15	22-84

The most common FAB subtypes accrued were M2, M1, M4 and M5. M3 was excluded because of the existence of effective treatment with the differentiating agent ATRA. This approximately reflects the reported incidence of AML in the population:

Table 8: FAB subtypes at initial presentation (M3 excluded)

Study	M0	M1	M2	M4	M4Eo	M5	M6,7	Unk.	Total
201	1	16	18	10	2	5	2	5	59
202	1	5	6	6	1	5		1	25
203	2	3	10	2		2		1	20
Total	4	24	34	18	3	12	2	7	104
AML*	5%	15%	25%	25%	5%	10%	15%		100%

*Reported incidence

Many patients in the study had unfavorable cytogenetics, which may reflect the tendency of this population to relapse. The two variables most closely correlated with response in relapsed AML are age and length of first remission, with older age and shorter remission carrying worse prognosis.

Table 9: Prognostic Characteristics at Relapse

Study		201	202	203	201/202/203
Accrual		59	25	20	104
Cytogenetics	favorable	1	2	0	3
	intermediate	24	10	10	44
	unfavorable	19	6	7	32
	Unknown	15	7	3	25
Prior Remission Duration	Mean (months)	16.7	21.3	8.9	16.4
	S.D.	14.7	27	7.6	17.9
	Range	6-95	5-117	3.3-34	3-117
Age	mean	52.7	57	70	57.1
	S.D.	15.8	12.1	7	15
	range	22-81	30-79	60-84	22-84

Reviewer comment: Most patients had unfavorable cytogenetics, probably reflecting the increased tendency of these patients to relapse. The decreased mean duration of prior remission in study 203 reflects the inclusion of patients with shorter duration of prior remissions in this study.

7.2.1.8. Efficacy endpoint outcomes

CRITERIA FOR EVALUATION:

Efficacy Assessment Methods:

Study part I: Efficacy was evaluated in terms of the number of patients who attained CR as the primary endpoint. CR was defined as

- the absence of leukemic blasts from the peripheral blood,
- the percentage of leukemic blasts in the bone marrow < 5%,
- the recovery of peripheral blood counts to the following levels - hemoglobin \geq 9 g/dL, platelets \geq 100,000/ μ L, absolute neutrophil count \geq 1500/ μ L; and
- red blood cell and platelet-transfusion independence. Red blood cell transfusion independence required no red blood cell transfusions for 2 weeks. Platelet transfusion independence required no platelet transfusions for 1 week.

The definition of MR is the same as that for CR except that platelet counts are \geq 100,000/ μ L and the patients are transfusion-independent for at least 10 days.

Study part II: The duration of CR or MR was evaluated as a secondary endpoint. Duration was evaluated for approximately 6 months after the end of the part I evaluation visit.

Poststudy part III: Investigational sites continued to follow patients enrolled in part II every 3 months for 18 months. Additionally, patients were monitored every 6 months after the 18-month follow-up period until death or termination of the study. These data will be analyzed in a separate poststudy report.

7.2.1.8.1. Results of efficacy analysis

The rates of CR were consistent across the 3 individual studies, ranging from 15% to 19%. The rates of MR were similar for the patients in studies 201 (15%) and 202 (16%); however, the rate of MR for the older patients in study 203 was lower (5%). The OR rate (CR + MR) was 34% in study 201, 32% in study 202, and 20% of patients in study 203. The overall rate of remission in the 3 pooled studies was 31%, including both the MR and CR's as responders. Eligibility was initially based on the local site readings of bone marrow aspirates or biopsies. Final enrollment eligibility was based on the flow cytometry measurements done by the central laboratory that verified that these patients did have > 5% blast cells and qualified as relapsed AML patients. Enrollment was not required to be confirmed by the independent pathologist. The independent pathologist was blinded to the patients' clinical course, to the time of the bone marrow sample, and to whether it was a screening or posttreatment sample.

For 7 patients, there was a discrepancy between the bone marrow evaluations of screening bone marrow samples reviewed by the independent pathologist and the readings done by the local site. An analysis was conducted by the sponsor excluding the responders in this group to explore the potential impact of these patients on the OR rate. Five (5) of the 7 patients had a CR or MR and 2 had NR. The OR rate decreased slightly to 28% when the 5 CR and MR patients were excluded from the remission category (Table 18). In these cases, the independent pathologist's opinion was that the blast cell percentage in the screening samples did not meet the criteria for relapsed AML. Because both the central flow cytometry laboratory and site readings classified these patients as having active leukemia, the sponsor has maintained the 5 responders in their efficacy analysis.

Reviewer Comment: Review of the data confirms the number and characterization of the responses. Minor inconsistencies between the local pathologist and the independent reviewing pathologist did not significantly alter the efficacy results.

Table 10: NUMBER (%) OF PATIENTS AND 95% CIs BY REMISSION CATEGORY IN PHASE II STUDIES

Type of Remission	Study 201^a (n = 59)	Study 202 (n = 25)	Study 203 (n = 20)	201/202 (n = 84)	201/202/203 (n = 104)
CR					
No. (%) of patients	11 (19)	4 (16)	3 (15)	15 (18)	18 (17)
95% CIs	(10, 31)	(5, 36)	(3, 38)	(10, 28)	(11, 26)
MR					
No. (%) of patients	9 (15)	4 (16)	1 (5)	13 (15)	14 (13)
95% CIs	(7, 27)	(5, 36)	(0, 25)	(9, 25)	(8, 22)
OR (CR + MR)					
No. (%) of patients	20 (34)	8 (32)	4 (20)	28 (33)	32 (31)
95% CIs	(22, 47)	(15, 54)	(6, 44)	(23, 44)	(22, 41)

a: Data from 1 patient (201-B2-0008) who had a bone marrow sample taken on day 20, rather than day 28, were also included in assessments.

If the MR's are included in the calculation of OR rates, a comparison with historical controls suggests that efficacy for gemtuzumab zogamycin is comparable to standard therapy in the higher risk patients, whose duration of first remission was < 1 year. The combined efficacy data for the three phase II studies showed an approximately 30% overall response rate, if the MR's are included, in patients whose first remission lasted less than one year. This is similar to the remission rates of 13-46% reported in several retrospective studies of patients whose remission lasted less than one year.

Patients whose first remission lasted greater than one year, who were able to tolerate chemotherapy, might have done somewhat better on standard induction therapy. In patients whose first remissions lasted over one year, remission rates were reported in the literature to be in the 50-60% range with standard induction therapy as compared with only 33% with the gemtuzumab zogamycin. (Table 11):

evidence of leukemia separately, and not to include them as nonresponders.”¹⁸ Therefore it is recommended that this group of patients with persistent thrombocytopenia but who meet other criteria for remission be reported separately from the complete responders.

Reviewer comment: The phenomenon of post-remission thrombocytopenia following myeloablative chemotherapy with or without hematopoietic stem cell transplantation is well described.¹⁹ The identification of several patients with apparent blast clearance and prolonged thrombocytopenia during phase I studies led the sponsor to initiate preclinical studies of the effects of mylotarg on megakaryocyte colony formation using samples of normal volunteers’ bone marrow, in order to see if any risk factors for thrombocytopenia could be identified. Megakaryocyte colony formation was assayed in the presence of mylotarg and found to be variably suppressed. Gene chip expression studies were performed using RNA derived from normal donors, to see if any correlation between megakaryocyte colony formation suppression and variations in the glutathione pathway and multiple drug resistance genes could be found, however, only 5 samples were studied and no correlation was identified. No definitive conclusions were made regarding the etiology of the thrombocytopenia, however, it seems likely that the study drug caused a suppression of the megakaryocyte lineage and subsequent prolonged thrombocytopenia.

Acute myeloid leukemia is more common in the elderly and the prognosis in elderly patients with AML is significantly worse than that observed in younger patients. Retrospective reviews have reported second remission rates of 14-44% in relapsed elderly patients with AML, and 33-54% in patients under 60. The 28% second remission rate observed in elderly patients treated with gemtuzumab zogamycin, is comparable to what is reported in the literature. Historically the younger patients have done somewhat better with conventional treatment (table 12):

Table 12: RETROSPECTIVE REVIEWS WITH > 100 PATIENTS AND GEMTUZUMAB ZOGAMICIN PHASE II CLINICAL TRIALS: % PATIENTS WITH SECOND REMISSIONS

Author, Institution	Total n	< 60 Years ^a			≥ 60 Years		
		n	(%)	CI ^b	n	(%)	CI ^b
Rees, MRC ^c	485	375	(33)	26-38	110	(19)	2 - 28
Keating, MD Anderson	187	208 ^d	(36)	29-42	35	(14)	5 - 30
Hiddemann, German Coop. Group	136	104	(54)	44-64	32	(44)	26 - 62
Davis, St. Bartholomew’s	126	NA	(40)	NA	NA	(40)	NA
Gemtuzumab zogamicin	104	50	(34)*	21-49	54	(28)*	16 - 42

Note: see previous table for references

* (CR+MR)

¹⁸ Cheson B et. al, Report on the National Cancer Institute-Sponsored Workshop on Definitions of Diagnosis and Response in Acute Myeloid Leukemia, Journal of Clinical Oncology 8:5, 813-819, 1990

¹⁹ Damon LE et. al. Post remission cytopenias following intense induction chemotherapy for acute myeloid leukemia, Leukemia 8:4, 535-541, 1994

Reviewer comment: Despite the inherent hazards of subset analysis and using historical controls as comparators, the data seems to suggest that patients with remission durations over one year historically may have done somewhat better with conventional therapy compared with gemtuzumab zogamycin, whereas the elderly and those with shorter remission times seemed to do less poorly compared with those with more favorable prognostic characteristics when treated with gemtuzumab zogamycin. There are insufficient numbers to make any definitive conclusions regarding these groups.

Although numbers are small, progression free survival and relapse free survival seem comparable between the CR's and the MR's although the MR's may have a slightly shorter RFS (Table 14):

Table 13: SUMMARY OF PROGRESSION-FREE SURVIVAL^a AND RELAPSE-FREE SURVIVAL^b (201/202/203)

Remission Group	n	Median (Months) ^c	Minimum (days)	Maximum (days)
Progression-free survival				
CR	18	9.6	83	673
MR	14	7.1	95	553
OR	32	9.5	83	673
Relapse-free survival				
CR	18	7.2	15	608
MR	14	4.4	21	510
OR	32	6.8	15	608

a: Survival measured from day of first dose

b: Duration of remission measured as relapse-free survival starting from the time CR or MR was achieved.

c: Medians are of the observed data and are not Kaplan-Meier estimates.

The sponsor has claimed that the MR group is clinically indistinguishable from the CR group in terms of RFS and PFS, and therefore that the MR group should be included in the calculation of OR.

Reviewer comment: The numbers are far too small to derive any conclusions regarding the comparability of these groups, however the MR group had somewhat shorter median survivals. There are too few patients to conclude if there are any meaningful differences in PFS and RFS between the MR and CR groups. The duration of second remission observed with gemtuzumab zogamycin is comparable to that reported in the literature with conventional therapy. Overall survival rates are similar in the MR and CR groups and worse in the NR groups (Table 14):

Table 14:SUMMARY OF LANDMARK SURVIVAL (201/202/203)

Group	n	Median* (days)	Minimum (days)	Maximum (days)
All patients	105	225	2	629
CR	18	379	63	629
MR	14	> 334	47	510
OR	32	> 379	47	629
NR	49	87	2	362

* Kaplan Meier Median, updated

One potential confounder for response duration is the therapy received by patients following attainment of remission. 60% of all patients and 72% of patients who achieved remission were given some kind of additional antileukemic therapy making it difficult to isolate the contribution of gemtuzumab zogamycin to the durations of response (Table 15):

Table 15: NUMBER (%) OF PATIENTS RECEIVING ADDITIONAL THERAPY AFTER GEMTUZUMAB ZOGAMICIN

Therapy	Transplantations	Other antileukemic therapy
All patients, n/total (%) 95% CI	21/104 (20) (13, 29)	41/104 (39) (30, 49)
CR, n/total (%) 95% CI	6/18 (33) (13, 59)	7/18 (39) (17, 64)
MR, n/total (%) 95% CI	7/14 (50) (23, 77)	2/14 (14) (2, 43)
OR, n/total (%) 95% CI	13/32 (41) (24, 59)	9/32 (28) (14, 47)
NR, n/total (%) 95% CI	8/72 (11) (5, 21)	32/72 (44) (33, 57)

21 patients went on to receive some kind of hematopoietic stem cell transplant. 3 patients received an autologous transplant and 18 patients received an allogeneic transplant (Table 16):

Table 16: SUMMARY OF SURVIVAL AND TREATMENT OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS

Cell Source	n	Survival		Treatment Outcome (after treatment with GZ)		
		30 Day	100 Day	CR	MR	NR
Autologous	3	3	2	2	1	0
BM	1	1	1	1	0	0
PBSC	2	2	1	1	1	0
Allogeneic	18	14	11	4	6	8
BM	8	5	4	2	2	4
PBSC	10	9	7	2	4	4
Total	21	17	13	6	7	8
BM	9	6	5	3	2	4
PBSC	12	11	8	3	5	4

The effect of the type of post remission therapy on survival is difficult to estimate. Recent studies in the literature suggest that autologous stem cell transplantation may not contribute a significant survival advantage to patients in first remission compared with high dose cytarabine or allogeneic transplants.²⁰ Patients who attained complete remissions following treatment with gemtuzumab zogamicin, seemed to do equally well whether or not they received a transplant, however patients who achieved a MR may have done somewhat better with a transplant, although the numbers are too small for meaningful comparisons (Table 17):

Table 17: RELAPSE-FREE SURVIVAL

Remission Group	n	Median (months)	Minimum (days)	Maximum (days)
CR	18	≥4.3	15	608
MR	14	≥2.6	21	510
OR	32	≥4.1	15	608
AFTER HSCT				
CR	6	≥ 4.3	23	586
MR	7	≥ 8.6	21	488
OR	13	≥ 5.1	21	586

Medians of the observed data, not Kaplan Meier estimates.

²⁰ Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. *N Eng J Med* 1998;339(23):1649-56.

Patients who went on to receive a transplant after attaining a remission survived a median total of at least 7.4 months (Table18):

Table 18: OVERALL SURVIVAL AFTER HSCT (201/202/203)

Remission Group	n	Median (months)	Minimum (days)	Maximum (days)
All patients	21	≥ 3.4	5	586
CR	6	≥ 5.6	23	586
MR	7	≥ 8.6	21	488
OR	13	≥ 7.4	21	586
NR	8	1.3	5	347

Medians are of the observed data and are not Kaplan-Meier estimates.

A multivariate analysis was used to try to determine predictors for response. The presence of CD 13 and CD 56 were found to decrease the likelihood of a response, as did a low baseline hemoglobin. Increase in CD33 expression mildly decreased the risk of death, as did an increase in the duration of prior remission. Presence of peripheral blasts and CD34 markers were strongly predictive of shorter survival (Table 19):

Table 19: RESULTS OF MULTIVARIATE EXPLORATORY ANALYSIS FOR PROGNOSTIC FACTORS

Analysis Variable	Wald Chi-Square p-Value	Odds Ratio ^a
OR versus NR^b		
CD13	0.005	0.03
MDR Efflux	0.009	0.97
Hemoglobin	0.015	1.71
CD56	0.026	0.08
Landmark Survival		
Quantitative CD33 expression	0.002	0.98
Duration of 1 st remission	0.013	0.92
Peripheral blood blasts	0.029	4.2
CD34	0.035	2.75

a: For CD13, CD56, and CD34, the ratios are for positive baseline values versus negative baseline values. For the other baseline values, the odds ratios and risk ratios are per unit increase in that prognostic variable.

b: The variables listed are those that were significant at the 0.05 level.

Conclusions: In the combined NDA studies, approximately 18% of patients treated with gentuzumab zogamicin attained a complete remission, according to traditional criteria. Another 15% of patients achieved clearance of blasts but never regained normal platelet counts, and this group was termed “morphologic remission.” RFS and OS seem to be similar for the two groups, suggesting that the thrombocytopenia seen in the MR group is not

indicative of residual leukemia. In addition, the survival of MRs following HSCT does not appear to be inferior to that of CR's following HSCT. Patient numbers however are too small to make any definitive conclusions regarding the similarity between these MR's and CR's. Some preclinical data suggests that the thrombocytopenia is a result of marrow toxicity of the study drug. If MR's are included in the analysis of overall response rates, gemtuzimab zogamicin appears to be comparable to conventional treatment in terms of remission rates except in those patients with relatively good prognosis whose duration of first remission exceeds one year. In the latter group, conventional therapy may be more efficacious. The duration of remission achieved with gemtuzimab zogamicin appears to be similar to that which is reported in the literature in those relapsed AML patients who do achieve a second remission.

7.2.1.9. Safety comparisons

Safety Assessment Methods:

Study part I: Evaluation included a physical examination, assessment of performance status, vital signs and possible drug-related toxicities, laboratory evaluations, chest X-ray film, electrocardiogram (ECG), and diagnostic tests for antibodies against calicheamicin and against the hP67.6 conjugate. In addition, all adverse events were documented in the adverse event record of the patient's case report form.

Study part II: All patients were followed for evaluation of serious adverse events associated with administration of further chemotherapy. In addition, responding patients had monthly interim physical examination, assessment of vital signs and performance status, and monthly complete blood count (CBC) with differential.

Poststudy part III: The overall patient status, including the duration of remission and survival was evaluated.

7.2.1.9.1.1. Safety results:

Since efficacy has not been demonstrated to be significantly improved over conventional therapy, the sponsor is applying for accelerated approval on the basis of improved safety profile. Specifically, the sponsor claims

- 1. Outpatient administration is feasible and safe. As with other antibody-based therapies, a mild infusion-related symptom complex was observed in most patients. These events were usually brief in duration without clinical sequelae.*

The infusion-related symptom complex is a recognized occurrence in patients treated with gemtuzumab zogamicin. The etiology is unclear but may be related to cytokine release and appears to be somewhat less common during the second dose. . Fever and chills were commonly reported despite prophylactic treatment with acetaminophen and antihistamin. One third of patients reported a grade 3-4 infusion – related adverse event. The incidence of severe hypotension was approximately 5% (5/104 patients had Grade 3 or Grade 4 hypotension) and these patients required intravenous fluid support and in one case dopamine. Hypotension resolved in all patients. 3 patients reported grade 3-4 hypoxia, which resolved spontaneously, and was treated with oxygen (Table 20):

Table 20: NUMBER (%) OF PATIENTS REPORTED TO HAVE THE MOST COMMON NCI GRADE 3 OR 4 SEVERITY INFUSION-RELATED TREATMENT-EMERGENT ADVERSE EVENTS BY DOSE^a (STUDIES 201/202/203)

Adverse Event	Dose 1 (n = 104)		Dose 2 (n = 88)	
	Grades 3 - 4	Grades 1 – 4 ^b	Grades 3 - 4	Grades 1 - 4
Any infusion-related adverse event	35 (34)	87 (84)	8 (9)	61 (69)
Chills	12 (12)	58 (56)	6 (7)	37 (42)
Fever	6 (6)	52 (50)	2 (2)	35 (40)
Hypotension	5 (5)	11 (11)	0	2 (2)
Leukopenia	5 (5)	6 (6)	2 (2)	3 (3)
Thrombocytopenia	5 (5)	6 (6)	1 (1)	5 (6)

a: Events occurring the day of gemtuzumab zogamicin administration. These TEAEs were reported for ≥ 5% of the patients in studies 201/202/203. Severity grades (mild, moderate, or severe) were merged to NCI toxicity grades (1, 2, or 3, respectively).

b: The Grades 1 – 4 columns include adverse events of any severity.

The primary reason for discontinuation was unsatisfactory response – lack of efficacy. 7 patients died prior to receiving a second dose of gemtuzumab zogamicin because of disease progression (Table 21):

Table 21: NO. PATIENTS (%) WHO DISCONTINUED FROM STUDY PART I – SUMMARY OF PRIMARY REASONS FOR DISCONTINUATION

Reason for Discontinuation	Number of patients
Adverse event	3
Unsatisfactory response – efficacy ^a	10
Other medical event (death in part I) ^b	7
Other medical event (HSCT)	1

7 patients had 2 primary reasons for discontinuation (unsatisfactory response and death), and are counted under both categories.

Reviewer comment: the administration of gemtuzumab zogamicin is probably safe in the outpatient setting, since most adverse events occurred within 4 hours of administration. It is considerably more convenient than conventional AML induction which requires 7 days of continuous inpatient intravenous infusion of cytotoxic medication. Discontinuations due to

adverse reactions were uncommon. However, the infusion center needs to be prepared to recognize and treat infusion-related hypoxic or hypotensive episodes.

2. *The safety profile of gemtuzumab zogamicin is comparable to that for conventional chemotherapies in terms of myelosuppression and bleeding but offers a safety advantage in terms of:*

- ◆ *Low incidence of severe mucositis*
- ◆ *Low incidence of severe infections*
- ◆ *Reduced median number of days of hospitalization due to both short outpatient infusion and decreased need for in-hospital supportive care.*
- ◆ *Only mild and reversible nausea and vomiting*
- ◆ *No alopecia*
- ◆ *Transient and reversible liver function test abnormalities occurred with moderate incidence*

Although the administration of gemtuzumab zogamycin is more convenient, the degree of myelosuppression achieved is comparable to that of conventional induction therapy. When compared with literature reports of adverse events occurring with conventional chemotherapy regimens, the incidence of severe mucositis is definitely reduced, and significant infection rates may be slightly lower. The risk of significant bleeding appears comparable to that of conventional therapy. In addition, there is a 31% incidence of abnormal grade 3-4 transaminases with GZ compared to 2-34% for conventional chemotherapy. Some of the newer regimens report increased toxicity and induction fatality rates compared with the older reports (Table 22):

Table 22: COMPARISON OF SAFETY RESULTS REPORTED IN LITERATURE^a WITH RESULTS FOR PATIENTS WHO RECEIVED GEMTUZUMAB ZOGAMICIN

Source	GZ	“medical literature” ^{b*}	HIDAC-M ²¹	DEM ²²
Adverse event (measurement)				
Median time to platelets > 100,000/L (days)	31.5 ^c	34-43	50	
Median time to ANC > 500/L (days)	22	23-40	40	34
Grade 3-4 Infections (%)	26	29-65.2	55	83
Grade 3-4 abnormal LFTs (%)	31 ^e	2-34	10	26
Grade 3-4 Bleeding (%)	14	9-25	10	21
Grade 3-4 Nausea or Vomiting (%)	14	3-30	20	27
CNS bleeding (%)	4	4-11	NR	NR
Grade 3-4 Mucositis (%)	2	3-27	12	23
Median duration of hospitalization (days)	20	38 ²³	NR	NR
Treatment mortality rate (%) ^j	13	3-27	10	32

- data compiled by sponsor

-

Although most clinical trial reports did not report on hospitalization rates, overall hospitalization days appeared to be reduced compared with historic controls²³. 5 patients (4 responders and 1 nonresponder) were treated without the necessity for any days in hospital, and 20 patients (11 responders and 9 nonresponders) required ≤ 7 days of hospitalization. Conventional induction requires 7 days of inpatient infusion which accounts for some of the observed differences in hospitalization days. Although the hospitalization and infection rates appear to be somewhat decreased, the incidence of hepatic dysfunction appears to be increased over that reported with conventional induction. 32 patients had at least one grade 3-4 grade 3 or 4 hepatic function abnormality during part 1, and 25 (24%) of patients showed severe (grade 3-4) elevations in bilirubin (Table 23):

²¹ HIDAC-M = cytarabine 1g/M² q12 x 4d + mitoxantrone 12 mg/ M² x 4d (see Kern W, *et al*: Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. *Leukemia* 1998;12:1049-55)

²² DEM = diaziquone + etoposide + Mitoxantrone (see Lee, EJ *et al*, An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia, *Leukemia*, 12: 139-143, 1998)

²³ Data compiled from a single study: Peterson, BA, Bloomfield, CD. Re-induction of complete remissions in adults with acute non-lymphocytic leukemia. *Leukemia Research*, ;5:81-8, 1981.

Table 23: NUMBER (%) OF PATIENTS WITH NON-HEMATOLOGIC LABORATORY TEST RESULTS OF CLINICAL IMPORTANCE IN PART 1

Test	Studies 201/202/203 (n = 104)		
	Grade 3	Grade 4	Total
Alkaline phosphatase	4/103 (4)	0	4/103 (4)
Calcium	10/103 (10)	5/103 (5)	15/103 (15)
Creatinine	1/103 (<1)	0	1/103 (<1)
Glucose	10/102 (10)	1/102 (<1)	11/102 (11)
AST	11/103 (11)	3/103 (3)	14/103 (14)
ALT	4/103 (4)	1/103 (<1)	5/103 (5)
Total bilirubin	18/103 (17)	7/103 (7)	25/103 (24)

Reviewer comment: Although it is sometimes difficult to ascribe the etiology of liver dysfunction in relapsed AML patients, it appears that this drug exhibits definite hepatotoxicity. Calicheamicin was noted to cause liver toxicity in preclinical testing, and it is likely that this is the etiology of the hepatic toxicity seen in these studies. In the clinical trials, most of the toxicity was transient and reversible, however one patient on study 201 exhibited persistent jaundice and ascites for several weeks following treatment. In addition, one patient with a history of VOD who relapsed following transplant was treated on a compassionate IND died following an episode of severe liver toxicity.

3. *Although MR patients had slower platelet recovery and required more platelet transfusions than CR patients, the overall safety profile of gemtuzumab zogamicin is comparable in CR and morphologic remission (MR) patients . The MR patients become transfusion-independent like the CRs, and there were no clinically meaningful differences in safety parameters including bleeding.*

Patients with MR's who by definition were more thrombocytopenic than CR patients required significantly more platelet transfusions prior to being declared MRs. There was a trend toward increased packed red blood cell requirements in the MR patients prior to the attainment of transfusion independence, as compared with the CR's. The CR and MR groups were therefore clinically distinguishable on the basis of platelet requirements, however the MR's exhibited a trend toward fewer packed red blood cell requirements than nonresponders (Table 24):

Table 24: NUMBER OF RED BLOOD CELL AND PLATELET TRANSFUSIONS^a
(STUDIES 201/202/203)

Parameter Statistic	Total (n = 104)	CR (n = 18)	MR (n = 14)	OR (n = 32)	NR (n = 72)
Number of red blood cell transfusions					
Mean (SD)	8.6 (26)	3.0 (3)	6.7 (7)	4.6 (5)	10.3 (31)
Median	5.0	1.5	4.5	3.0	5.5
Approx 95% CI ^b	(4, 6)	(1, 4.5)	(2.5, 12)	(2.5, 5.5)	(4.5, 6.5)
95% CI for MR-CR	(-1, 4)				
Number of platelet transfusions					
Mean (SD)	16.7 (29)	5.3 (5)	15.8 (12)	9.9 (10)	19.7 (33)
Median	11.0	4.5	11.0	7.5	13.0
Approx 95% CI	(10, 14.5)	(2.5, 7.5)	(8.5, 23)	(5.5, 12)	(11.5, 17)
95% CI for MR-CR	(2, 17)				

a: All transfusions occurring in part I of the phase II studies.

b: Non-parametric confidence intervals.

CR = complete remission; MR = morphologic remission;

OR = overall remission rate (CR + MR); NR = no remission.

Bleeding is a common and potentially serious complication of AML, most often due to thrombocytopenia. Sometimes bleeding is exacerbated by a coagulopathy especially DIC, although the protocol excluded M3 AML which is most commonly associated with DIC. Bleeding varied in severity from petechiae and mild epistaxis to fatal hemorrhages. One patient died of retroperitoneal hemorrhage, one patient who was treated with a preexisting coagulopathy (DIC) developed a fatal intracerebral hemorrhage within 5 hours of treatment, and another patient who was thrombocytopenic developed an intracranial hemorrhage 1 day after treatment. The numbers are too small to derive any conclusions regarding these adverse events. 3 patients died of cerebral hemorrhage >30 days from the last dose of study medication; it was not clear that these events were related to the study medication. The overall incidence of bleeding as an adverse event appeared to be similar in the CR and MR group and increased in nonresponders (Table 25):

Table 25: NUMBER (%) OF PATIENTS REPORTING \geq 5%^a BLEEDING TREATMENT-EMERGENT ADVERSE EVENTS IN PART I BY TREATMENT OUTCOME CATEGORY (STUDIES 201/202/203)

Bleeding Adverse Event ^b	Total (n = 104)	CR (n = 18)	MR (n = 14)	OR (n = 32)	NR (n = 72)
Ecchymosis	15 (14)	1 (6)	1 (7)	2 (6)	13 (18)
Epistaxis	32 (31)	4 (22)	4 (29)	8 (25)	24 (33)
Gum hemorrhage	12 (12)	2 (11)	1 (7)	3 (9)	9 (13)
Hematemesis	6 (6)	0	0	0	6 (8)
Hematuria	10 (10)	0	2 (14)	2 (6)	8 (11)
Hemoptysis	5 (5)	0	1 (7)	1 (3)	4 (6)
Hemorrhage	11 (11)	0	0	0	11 (15)
Menorrhagia	2 (5)	0	1 (14)	1 (7)	1 (3)
Metrorrhagia	4 (9)	1 (14)	1 (14)	2 (14)	2 (7)
Petechiae	22 (21)	1 (6)	3 (21)	4 (13)	18 (25)
Rectal hemorrhage	6 (6)	0	1 (7)	1 (3)	5 (7)
Vaginal hemorrhage	5 (11)	1 (14)	0	1 (7)	4 (13)

a: \geq 5% limit specifies the minimum percentage from the total of 104 patients.

b: Percentages of sex-specific adverse events are based on the number of patients of the relevant sex.

CR = complete remission; MR = morphologic remission; OR = overall remission rate (CR + MR);

NR = no remission.

4. *No patients developed an immune response to gemtuzumab zogamicin in the phase II studies*

During the phase I trials, 40 patients were tested for the formation of antibodies to gemtuzumab zogamicin; and 2 were positive. One (1) patient experienced a CR at 1 mg/m² and subsequently received a second course of gemtuzumab zogamicin at 6 mg/m² at the time of next relapse). This patient developed antibodies to the calicheamicin/linker portion of gemtuzumab zogamicin, and had transient shortness of breath that was associated with immune reaction to the gemtuzumab zogamicin conjugate. Antibody formation to the calicheamicin/linker portion appeared to be dose independent, as the second patient developed these antibodies after the third dose of 0.25 mg/m² gemtuzumab zogamicin.

In the phase II studies, patients were screened for antibodies directed against the calicheamicin/linker portion of gemtuzumab zogamicin and to the antibody portion. In 104 patients and 196 doses, none of the patients studied had any antibody responses or clinical evidence of immune response. Four (4) patients received a second course (4 doses total) of gemtuzumab zogamicin therapy and did not develop anti-gemtuzumab zogamicin antibodies.

7.2.1.9.2. Pharmacokinetic/ Pharmacodynamic Results:

The highest concentrations of hP67.6 and calicheamicin were observed shortly after the end of the 2 hour infusion for all patients. The concentration profile of both total calicheamicin and unconjugated calicheamicin followed essentially the same time course as hP67.6. Pharmacokinetics data showed extreme variability. The change in pharmacokinetic parameters across dose periods may be related to measures of changing antigen burden in the body, or to inaccuracies of the assay technique. The ratio of total calicheamicin AUC to hP67.6 AUC was 1.92% for the first dose period and 2.66% for the second dose period. The ratio of unconjugated calicheamicin AUC to hP67.6 AUC was 0.273% for the first dose period and 0.163% for the second dose period. (See Dr. Kieffer's PK review).

7.3. Significant/Potentially Significant Events

7.3.1. Deaths

7.3.1.1. Phase I trials

Seven (7) patients died during the study or within 30 days of their last dose of gemtuzumab zogamicin. These patients are shown in Table 10.4.1A. Other deaths are shown in Table 10.4.1B. The treatment relationship of these deaths was assessed inconsistently by the investigators. The majority of the deaths were the result of the underlying disease progression in this patient population. However, 2 patients died from infection. Another patient had prolonged neutropenia and a patient had sepsis, both leading to death. Both of these events were judged probably treatment related by the investigator.

7.3.1.2. Phase 2 trials

14 patients died within 30 days of receiving gemtuzumab zogamicin. The most common reason for treatment related death was disease progression (6 patients). Three patients died as a result of cerebral bleeding and 3 patients died from multisystem organ failure. Two patients died from sepsis (Table 26):

Table 26: SUMMARY OF DEATHS THAT OCCURRED IN PART I OF STUDIES 201/202/203

Dose	Patient	Age (y) / Sex	Day ^a	Cause of Death
Dose 1				
	201A9-0008	49 / M	2	L Frontoparietal intraparenchymal hemorrhage.
	20363-0001	62 / F	18	Disease progression (AML).
	201B2-0002	24 / M	18	Sepsis.
	201B0-0001	36 / M	20	Multisystem deterioration
	20378-0002	80 / F	20	Disease progression.
	20372-0001	84 / F	21	Hyperkalemia, bradycardia, hypotension, renal failure, acute pulmonary edema
	201B4-0001	64 / F	22	Disease progression.
Dose 2				
	20365-0001	70 / F	17	Intracerebral hemorrhage due to thrombocytopenia.
	20278-0002	48 / M	25	Frontal lobe bleeding.
	201A9-0001	44 / M	27	Neutropenic fever. Progression of leukemia.
	201A9-0004	45 / M	31	Sepsis secondary to disease progression.
	201B1-0004	24 / F	35	Multisystem organ failure.
	20276-0001	53 / M	37	Respiratory failure.
	20357-0004	60 / M	42	Leukemia progression.

a: Day relative to the start of the study.

The overall treatment-related mortality rate was 13%, as compared with 10-30% reported in previously cited studies of relapsed AML. Mortality was primarily related to disease progression.

7.3.2. Other Serious Adverse events

96 patients experienced grade 3-4 events, and 17 patients experienced serious and unexpected events. 4 of these events were judged probably related to the drug, and 12 possibly related in the opinion of the investigator. Most of these events were related to progression of the disease, however there was one patient who experienced persistent hyperbilirubinemia which may have been related to the study drug (Table 27):

Table 27: PATIENTS EXPERIENCING SERIOUS AND UNEXPECTED ADVERSE EVENTS (STUDIES 201/202/203)

“probably related” to the study drug, (in the opinion of the investigator)			
Age / Sex	Primary Event	Other conditions	Outcome
24 / M	severe lower back pain,	hypophosphatemia, hyperkalemia, bradycardia	Resolved
60 / F	neutropenic fever	diabetes insipidus	Resolved
43 / F	Fever	cyanosis, hypoxia, rigors,	Resolved
67 / M	nose bleeding, fever;	bone marrow aplasia > 8 weeks	Resolved
“Possibly Related” to the study drug, in the opinion of the investigator			
65 / M	hip pain and neutropenia;	fungal infection	Died
51 / M	neutropenic fever and joint pain	tenosynovitis	Resolved
81 / F	Rectal bleeding and vaginal bleeding		Resolved
74 / M	ascites, jaundice	Hyperbilirubinemia, hepatosplenomegaly	Persistent
75 / M	diffuse fluid retention, R pleural effusion, and ascites		Resolved
72 / F	seizures		Resolved
36 / F	Hospitalization for neutropenic fever and	L orbital cellulitis	Resolved
66 / M	hemoptysis and epistaxis; fever	bleeding from the bone marrow aspirate site	Resolved
75 / M	exacerbation of DIC, bone pain	aplasia	Resolved
75 / M	Hypertension crisis and	fever	Resolved
70 / F	Intracerebral hemorrhage		Died
69 / F	allergic reaction, hypotension	exacerbation of pre-existing DIC	Resolved

7.4. Overview of Safety

Gemtuzumab zogamicin offers improved convenience of administration compared with conventional chemotherapy for relapsed AML. Hospitalization days and rates of severe infection, and mucositis, appear to be decreased compared to that reported in the literature for conventional chemotherapy. Nausea, vomiting, bleeding and myelosuppression appear to be comparable to historical controls, however elevation in transaminases and bilirubin appears to be somewhat more frequent than that reported in the literature.

7.4.1. Overdosage exposure

No cases of overdose with [] were reported in clinical experience. Single doses higher than 9 mg/m² in adults were not tested.

7.4.2. Drug-Demographic Interactions

Effect of Age

Patients ≥ 60 years comprise approximately 50% of AML patients and represent a distinct challenge in AML therapy. There are patient and disease factors that result in a poor outcome in these patients. Of note, there were no pharmacokinetic differences to suggest that gemtuzumab zogamicin dosing needs to be altered in patients ≥ 60 years old. The most common TEAEs (those reported by ≥ 30% of patients) in patients ≥ 60 years of age were: fever, chills, nausea, vomiting, thrombocytopenia, leukopenia, asthenia, diarrhea, abdominal pain, headache, stomatitis, dyspnea, anorexia, hypokalemia, and epistaxis. The following TEAEs were identified as being reported more commonly for patients < 60 than those ≥ 60 years of age: abdominal pain, headache, myalgia, chills, hypomagnesemia, herpes simplex, gum hemorrhage, and stomatitis. Similarly, some TEAEs were identified as being reported more commonly for patients ≥ 60 than for those < 60 years of age. These TEAEs were peripheral edema, back pain, pain, dry mouth, anemia, lactic dehydrogenase increased, insomnia, and constipation. There were considered to be no clinically important differences in TEAEs between the two age groups of patients. Bilirubin had statistically significant and clinically important patterns of change in patients ≥ 60 years old only. In addition, AST, which did have statistically significant and clinically important patterns of change in the phase II patients as a whole, had consistent changes between dose periods 1 and 2 for patients ≥ 60 years old but not for patients < 60 years old. ALT had statistically significant and patterns of change only in patients ≥ 60 years old. These data suggest that changes in some laboratory parameters associated with hepatic dysfunction were more consistently observed in patients ≥ 60 years old than in those < 60 years old.

Reviewer comment: These findings should be considered for inclusion in labeling.

Effect of sex

The following TEAEs were identified as being reported more commonly for female than for male patients: headache, dehydration, and ecchymosis. Similarly, some TEAEs were identified as being reported more commonly for male than for female patients. These TEAEs were cough increased, pharyngitis, tachycardia, AST increased, hypertension, diarrhea, hyperbilirubinemia, dyspnea, herpes simplex, hematemesis, petechiae, pneumonia, hematuria, hemorrhage, hypervolemia, edema, and arthralgia. There were considered to be no clinically important differences in TEAEs between the female and male patients.

Effect of Ethnic Origin

Because the vast majority of patients enrolled in gemtuzumab zogamicin clinical trials have been white, an analysis of safety or efficacy by ethnicity would not be meaningful.

7.4.3. Drug-Disease Interactions

The extreme variability in $t_{1/2}$ was postulated as possibly related to the total body load of CD33 positive blasts, however, this has yet to be confirmed.

7.4.4. Drug-Drug Interactions

None known

7.4.5. Withdrawal Phenomena/Abuse Potential

None known

7.4.6. Human Reproduction Data

See pharmacologic review

8. Conclusions

Gemtuzumab zogamicin, an innovative anti CD33 monoclonal antibody conjugated to calicheamicin, showed modest efficacy in the treatment of CD 33 positive relapsed acute myeloid leukemia in these clinical trials. A significant portion of patients achieved clearance of blasts but exhibited prolonged thrombocytopenia following treatment. These patients initially required significantly more platelet transfusions and showed a trend towards more red cell transfusions, however they eventually attained transfusion independence. Remission durations in the patients with persistent thrombocytopenia appeared comparable to those patients whose platelets recover above 100,000 and have a comperable overall survival after subsequent hematopoetic stem cell transplant. These patients therefor appear to have sustained a clinically meaningful response. Comparison with historical controls suggests that patients with the favorable prognostic characteristic of longer duration of first remission who are able to tolerate conventional re induction chemotherapy, may have a somewhat greater chance of attaining remission with conventional treatment.

Improved ease of administration, reduced severe mucositis and infection rates appear to decrease hospitalization rates and may allow some patients to achieve a remission without the necessity of hospitalization. Severe elevations of hepatic transaminases, with or without hyperbilirubinemia, are generally transient but sometimes persist.

Accelerated approval of a new agent for use in the treatment relapsed acute myeloid leukemia may be based on the demonstration of improved safety and comparable efficacy to conventional chemotherapy. We ask the ODAC to consider and advise on the following issues:

1. Comparability of morphologic responses and complete responses in terms of efficacy and safety outcomes;
2. Comparability of better prognosis and worse prognosis patients in terms of efficacy and safety outcomes; in particular the outcomes in patients with a first remission \geq one year should be discussed;
3. Comparison of the safety profile of GZ to other available therapies for relapsed leukemia patients in general and for elderly patients in particular.

Peter F., Bross, M.D.

Date

Julie Beitz, M.D.

Date

CC: Orig NDA

Division file, HFD-150

9. Appendices

9.1. Appendix 1: Study Flow Chart:

Study Schedule Visit	Screening	TABLE 6.1.2.1A.		STUDY FLOWCHART PART I											
		Baseline		Study Period											
		Cycle 1		Cycle 2 ^a											
Study Week		1	2	3	4	5	6	7							
Study Day (approximate)	-7 to 1	1	8	15	22	29	36	43 ^b							
Medical History	X														
Complete Physical Exam ^c	X														X
CBC with Differential ^d	X	X ^e	X	X	X	X	X	X	X ^e	X	X	X	X	X	X
Blood Chemistry	X	X ^e	X	X	X	X	X	X	X ^e	X	X	X	X	X	X
PT, PTT	X														X
Chest X-ray	X														X
ECG	X	X ^e													X
-HCG	X ^f														
Urinalysis	X														X
Bone Marrow Aspirate	X ^g			X							X				X
Bone Marrow Biopsy	X ^g										X ^g				X ^h
Plasma Samples for PK		X ^{e,i}	X		X	X			X ^{e,i}	X		X	X		X
Whole Blood for CD33		X ^{e,i}							X ^{e,i}						
Saturation															
Antibody against gemtuzumab zogamicin ^j		X ^e		X							X				X
Pretreatment Medications		X ^k							X ^k						
Study Drug Administration		X							X ^a						
Interim Physical Exams ^{c,l}		X ^{e,i}	X		X	X			X ^{d,e}	X		X	X		X
Monitor Study Events		X		X					X		X			X	X

a: Patients were eligible to receive dose 2 provided the following conditions were met before each dose: the patient had recovered from reversible nonhematologic toxicities resulting from the previous doses; there was no evidence of disease progression; there was no evidence of significant formation of antibodies reactive with calicheamicin or protein; at least 14 days, but not more than 28 days, had passed since the previous infusion. In the event that patients were not eligible for subsequent doses and were withdrawn from the study, procedures outlined for the time frame from dose 2 to the end of part I evaluation visit were to be followed beginning with the corresponding day in the dose period. For selected patients possibly eligible for an additional dose, study procedures were to be followed as for doses 1 and 2.

b: End of part I evaluation (day 43 if the patient received 2 doses OR 28 days following the last dose of study medication). All patients were to enter part II and be evaluated approximately monthly to document survival status and antileukemic therapy. In addition, all patients with no leukemic blasts in the peripheral blood and $\leq 5\%$ blasts in the bone marrow (measured by bone marrow aspirate or biopsy) at the end of part I visit were to have monthly interim physical examinations (including vital signs and performance status), as well as monthly CBC with differential. All patients receiving HSCT or additional antileukemic therapy in part II were to have information collected regarding responses to these therapies.

c: Including performance status. : CBCs were to be performed Monday, Wednesday and Friday (or on alternate days in a similar pattern) for the first 2 weeks after infusion of GZ or until recovery of granulocytes and platelets, to $\geq 1500/\mu\text{L}$ and $\geq 100,000/\mu\text{L}$ respectively, whichever came first. Additional CBCs were to be performed as clinically indicated.

c: Including performance status.

d: CBCs were to be performed Monday, Wednesday and Friday (or on alternate days in a similar pattern) for the first 2 weeks after infusion of GZ or until recovery of granulocytes and platelets, to $\geq 1500/\mu\text{L}$ and $\geq 100,000/\mu\text{L}$ respectively, whichever came first. Additional CBCs were to be performed as clinically indicated.

e: Before dose administration.

f: For women of childbearing potential, β -HCG serum pregnancy test was to be performed within 1 week before the first dose of study medication.

g: Bone marrow aspirate/biopsy was performed to confirm diagnosis of CD33 positive AML. Slides for morphologic evaluation of bone marrow aspirate and biopsy were sent for review by an independent consultant. Histochemical stains were to be performed by each investigational site on prestudy specimens only. An aliquot of bone marrow aspirate was to be sent for immunophenotyping by Hematologics, Inc. at FHCRC; an aliquot of bone marrow aspirate was also to be provided for analysis of leukemic cell MDR efflux and in vitro sensitivity to gemtuzumab zogamicin (Dr. Bernstein's lab - FHCRC). Bone marrow biopsies obtained within 14 days before dose administration were acceptable. Bone marrow biopsy was required on patients who were to receive a third cycle of gemtuzumab zogamicin.

h: For patients who discontinued dose administration and did not receive 2 doses of gemtuzumab zogamicin, there was no need to obtain the final bone marrow biopsy.

i: See study drug infusion/PK flowchart for schedule for obtaining vital signs and blood samples during the study drug infusion observation period. (Vital signs included blood pressure, heart rate, respiratory rate, and oral temperature except where otherwise noted on the study drug infusion/PK flowchart.)

j: Subsequent dose administration could NOT proceed until verification was provided by W-AR regarding the absence of significant formation of antibodies against calicheamicin and hP67.6 antibody.

k: Patients were pretreated with acetaminophen and diphenhydramine approximately 1 hour before study drug administration; 2 additional doses of acetaminophen were administered; 1 at approximately 4 hours, and the other at approximately 8 hours, after the initial pretreatment dose.

l: At least twice weekly for the first 2 weeks after infusion of study drug; including assessment of performance status and vital signs at each interim physical examination.

Abbreviations: MDR = multiple-drug resistances

9.2. Appendix 2: Proposed Labelling

[] is indicated for the treatment of patients with CD33 positive acute myeloid leukemia in relapse.

CLINICAL STUDIES

The efficacy and safety of [] as a single agent were demonstrated in a pivotal open-label study conducted in 59 patients with CD33 positive AML in first relapse. The treatment phase included two 9 mg/m² doses separated by 14 days and a 28-day follow-up after the last dose. Two supportive open-label studies provided additional efficacy and safety data. One of these, a study similar in design to the pivotal study, had 25 patients enrolled and like the pivotal trial required that the duration of first remission be at least 6 months.

The second supportive study included 20 patients in first relapse who were \geq 60 years of age and required the duration of first remission to be at least 3 months. In these studies, a total of 104 patients were evaluated.

In these studies, complete remission (CR) was defined as

- a) leukemic blasts absent from the peripheral blood;
- b) $<$ 5% blasts in the bone marrow as measured by morphology studies;
- c) hemoglobin (Hgb) $>$ 9 g/dL, platelets $>$ 100,000/ μ L, absolute neutrophil count (ANC) $>$ 1500/ μ L; and
- d) red-cell and platelet-transfusion independence (no red cell transfusions for 2 weeks; no platelet transfusions for 1 week).

In the efficacy and safety studies, a set of additional remission patients have been identified who did not meet the strict definition of CR. This category (CRp) included patients who satisfied the definition of CR, including leukemic blast cell clearance and platelet-transfusion independence, with the only exception of platelet recovery \geq 100,000/ μ L. Ninety-three percent (93%; 13/14 CRp patients) achieved platelet counts of 25,000/ μ L and 71% (10/14 CRp patients) achieved platelet counts of 50,000/ μ L, before any additional therapy was administered. The CR and CRp patients are clinically comparable in terms of relapse-free and overall survival rates, adverse event profile, and number of days in the hospital. Thus, the efficacy of MYLOTARG is expressed as an overall rate of remission (OR), defined as CR plus CRp.

[

]

[

]

INDICATIONS AND USAGE

[] is indicated for the treatment of patients with CD33 positive acute myeloid leukemia in relapse.

CONTRAINDICATIONS

[] is contraindicated in patients with a known hypersensitivity to gemtuzumab zogamicin or any of its components: anti-CD33 antibody (hP67.6), calicheamicin derivatives, or excipients.

WARNINGS

[] is intended for administration under the supervision of a physician who is experienced in the use of cancer therapeutic agents.

Severe myelosuppression will occur in all patients given a therapeutic dose of this agent. Careful hematologic monitoring is required.

Patients being treated for leukemia are at increased risk of developing opportunistic infections and bleeding. As with all therapies for AML, virtually all patients treated with [] experienced some degree of anemia as well as severe neutropenia and thrombocytopenia.

[] can produce a post-infusion symptom complex of fever and chills, and less commonly hypotension and dyspnea, that may occur during the first 24 hours after [] administration. Grade 3 or 4 infusion-related adverse events included chills (13%), fever (8%), hypotension (5%), and dyspnea (2%). Most patients in the efficacy and safety studies received the following prophylactic medications before [] administration, one dose of diphenhydramine 50 mg po and one dose of acetaminophen 650- 1000 mg po; thereafter, two additional doses of acetaminophen 650-1000 mg po, one every 4 hours as needed.¹⁷

PRECAUTIONS

DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS

General: Treatment should be initiated by and remain under the guidance of appropriately qualified specialists in hematology/oncology.

Tumor lysis syndrome is an anticipated consequence of effective treatment of leukemia. Patients should be cared for in a manner that anticipates this consequence.

Appropriate measures must be taken to prevent hyperuricemia and to control any systemic infection before beginning therapy.

Laboratory Monitoring: Complete blood counts (CBCs) and platelet counts should be monitored during [] therapy, and more frequently in patients who develop cytopenias.

Drug Interactions: There have been no formal drug interaction studies performed with []

Laboratory Test Interactions: [] is not known to interfere with any routine diagnostic tests.

Antibody formation: Antibodies to gemtuzumab zogamicin were not detected in any of the patients in the efficacy and safety studies.^{11,12,13} Two (2) patients in the phase I study developed antibody titers against the calicheamicin/calicheamicin-linker portion of gemtuzumab zogamicin. One (1) of these patients experienced transient, reversible symptoms suggestive of an immune response, the other had no clinical symptoms.¹⁸

Carcinogenesis, Mutagenesis, Impairment of Fertility: No long-term studies in animals have been performed to evaluate carcinogenic potential of []. [] was mutagenic in the mouse micronucleus test. This positive result is consistent with the known anti-tumor mechanism of action of calicheamicin, which causes double-stranded breaks in DNA. The effect of [] on fertility in human is unknown.

Degeneration of the testis/accessory sex organs was seen following 6 cycles of dosing in rats and in monkeys.

Pregnancy Category C: [] has been shown to be teratogenic and embryotoxic in rats when given a total dose of 1.7 mg/m².¹⁹ There are no adequate and well-controlled studies in pregnant women. [] should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.

Nursing Mothers: It is not known if [] is excreted in human milk. Because many drugs, including immunoglobulins, are excreted in human milk, formula feeding is recommended when [] is administered to nursing women.

Pediatric Use: The safety and effectiveness of [] in pediatric patients have not been fully established.

Use in Patients With Hepatic Impairment: Patients with hepatic impairment were not included in the studies.

Use in Patients With Renal Impairment: Patients with renal impairment not included in the studies.

ADVERSE REACTIONS

In three efficacy and safety studies, 104 patients were administered [] at 9 mg/m². [] was generally given as 2 IV infusions scheduled 14 days apart. The clinical experience includes 50 patients less than 60 years of age, and 54 patients 60 years of age or older.

Infusion-related events (on the same day of [] administration). An infusion-related symptom complex consisting of fever and chills occurred in the majority of patients on the same day of [] administration. Chills occurred in 63% of patients and fever occurred in 62% of patients. Less common symptoms included headache (15% of patients), hypotension (12% of patients), and dyspnea (5% of patients). The incidences of more serious clinical events (Grade 3 or 4) were chills (13%), fever (8%), hypotension (5%), and dyspnea (2%). These symptoms generally occurred after the end of the 2-hour [] IV infusion, lasted 2 to 4 hours, and resolved with supportive therapy (acetaminophen, diphenhydramine, IV fluids). There tended to be a lower incidence of infusion-related events after the second dose than after the first dose.²¹

Adverse events that caused discontinuation of treatment: In the phase I ascending-dose study, 1 of 40 patients who received [] discontinued treatment because of an adverse clinical event (worsening of hypotension). In the efficacy and safety studies, 1/104 (1%) patient who received [] discontinued treatment because of an adverse event. This patient experienced a tonic/clonic seizure.²⁰

Hematologic Events:

Severe myelosuppression is the major toxicity associated with [] therapy and is a consequence of targeting CD33 antigen, which is expressed on some hematopoietic progenitor cells. Due to the underlying pathophysiology of their disease, patients receiving [] experienced substantial numbers of hematologic laboratory abnormalities.

During the treatment phase, 15/104 (14%) patients experienced Grade 3 or Grade 4 bleeding of all types. The most frequent severe TEAEs were epistaxis (3%) and cerebral

hemorrhage (3%). There were also reports of hematuria (2%) and disseminated intravascular coagulation (1%).

During the treatment phase, 101/103 (98%) patients experienced Grade 3 or Grade 4 thrombocytopenia, 98/101 (97%) patients experienced Grade 3 or Grade 4 neutropenia, 99/103 (96%) patients experienced Grade 3 or Grade 4 leukopenia, and 50/103 (49%) patients experienced Grade 3 or Grade 4 anemia.

Responding patients recovered from Grade 4 neutropenia by a median of 22 days and from Grade 4 thrombocytopenia by a median of 15 days after the last dose of [].

Non-hematologic Events:

Mucositis and infections are adverse reactions that are of special interest in the treatment of patients with leukemia.

A total of 43/104 (41%) patients were reported to have a TEAE consistent with mucositis or stomatitis. During the treatment phase, 2/104 (2%) patients experienced Grade 4 stomatitis after the first dose. The mucositis events for the remaining 41/104 (39%) patients were categorized as Grade 1 or 2.

During the treatment phase, 27/104 (26%) patients experienced Grade 3 or Grade 4 infections of all types. This represented 31% (27/87) of the infection-related TEAEs. The most frequent Grade 3 or Grade 4 infection-related TEAEs were sepsis (14%) and pneumonia (7%).

During the treatment phase, 25/103 (24%) patients experienced Grade 3 or Grade 4 bilirubinemia, 5/103 (5%) patients experienced Grade 3 or Grade 4 abnormalities in levels of ALT, and 14/103 (14%) patients experienced Grade 3 or Grade 4 abnormalities in levels of AST. Abnormalities of liver function were transient and generally reversible.

Retreatment Events: Four (4) patients have received more than one course of [], 3 of these patients at 9 mg/m². The adverse event profile for retreated patients was similar to that following their initial treatment. One of the repeat dose patients was in the phase I study and received a first course of 3 doses at 1 mg/m² and 2 doses of a second course at 6 mg/m². This patient was discontinued from further dose administration as a result of an immune response to the calicheamicin/ calicheamicin-linker portion of gemtuzumab zogamicin. The 3 other retreated patients did not experience an immune response.

Dose relationship for adverse events: Dose-relationship data were generated from a phase I dose-escalation study. The most common clinical adverse event observed in this study was an infusion-related symptom complex of fever and chills. In general, the severity

of fever, but not chills, increased as the dose level increased. Only one dose level of [] was studied in the efficacy and safety studies.

Treatment-emergent adverse events (TEAE): TEAEs that occurred in $\geq 10\%$ of the patients are listed in Table 3.²¹

TABLE 3. PERCENT (%) OF PATIENTS REPORTING TREATMENT-EMERGENT ADVERSE EVENTS (INCIDENCE $>10\%$) ^a	
Body system Adverse event	Efficacy and Safety Studies (n = 104)
Body as a whole	
Abdominal pain	40
Asthenia	48
Back pain	17
Chest pain	11
Chills	74
Fever	85
Headache	40
Infection	10
Neutropenic fever	22
Pain	19
Sepsis	26
Cardiovascular system	
Hemorrhage	11
Hypertension	20
Hypotension	23
Tachycardia	13
Digestive system	
Anorexia	31
Constipation	22
Diarrhea	41
Dyspepsia	13
Gum hemorrhage	12
Nausea	73
Stomatitis	38
Vomiting	64
Hemic and lymphatic system	
Ecchymosis	14
Petechiae	21
Metabolic and nutritional	
Hypokalemia	31
Hypomagnesemia	11
Hypophosphatemia	10
Lactic dehydrogenase increased	13
Peripheral edema	18
Nervous system	
Depression	11
Dizziness	18
Insomnia	17
Respiratory system	
Cough increased	18

Dyspnea	32
Epistaxis	31
Pharyngitis	14
Pleural effusion	10
Pneumonia	10
Pulmonary physical finding	11
Rhinitis	10
Skin and appendages	
Herpes simplex	24
Rash	24
Urogenital system	
Hematuria	10
Vaginal hemorrhage ^b	11
Miscellaneous	
Local reaction to procedure	25
a: Selected laboratory events are reported in Table 5.	
b: Incidence based on women only.	

TABLE 4. PERCENT (%) OF PATIENTS REPORTED TO HAVE NCI GRADE 3 OR 4 SEVERITY TREATMENT-EMERGENT ADVERSE EVENTS ^{a,b} (INCIDENCE > 5%)

Body system adverse event	Efficacy and safety studies (n = 104)	
	Grades 3 - 4	All grades (1 - 4)
Body as a whole		
Asthenia	8	48
Chills	16	74
Fever	15	85
Neutropenic fever	6	22
Sepsis	14	26
Cardiovascular system		
Hypertension	8	20
Hypotension	11	23
Digestive system		
Nausea	9	73
Vomiting	5	64
Metabolic and nutritional		
Lactic dehydrogenase increased	5	13
Respiratory system		
Dyspnea	10	32
Pneumonia	7	10
Miscellaneous		
Local reaction to procedure	5	25

a: NCI toxicity is regarded as the maximum intensity reported for the adverse events.

b: Selected laboratory events are reported in Table 5.

Selected laboratory values with a Grade 3 or 4 severity (NCI toxicity scale) are listed in Table 5.²²

TABLE 5. PERCENT (%) OF PATIENTS WITH POTENTIALLY CLINICALLY IMPORTANT LABORATORY VALUES (INCIDENCE \geq 5%)^a

Category Laboratory Test	Grades 3 - 4 (n = 103)
Hematology	

Anemia	49
Thrombocytopenia	98
Neutropenia	97 ^b
Leukopenia	96
Chemistry	
Increased ALT	5
Increased AST	14
Hypocalcemia	15
Hyperglycemia	11 ^c
Hyperbilirubinemia	24

a: NCI toxicity is regarded as the maximum intensity reported for the adverse events.

b: n = 101.

c: n = 102.

OVERDOSAGE

Human: No cases of overdose with [] were reported in clinical experience. Single doses higher than 9 mg/m² in adults were not tested.

Signs and Symptoms: Signs of overdose with [] are unknown.

Recommended Treatment: General supportive measures should be followed in case of overdose. Blood pressure and blood counts should be carefully monitored. Gemtuzumab zogamicin is not dialyzable.

DOSAGE AND ADMINISTRATION

The recommended dose of [] is 9 mg/m², administered as a 2-hour intravenous infusion. The recommended treatment course with [] is a total of 2 doses with 14 days between the doses. Full recovery from hematologic toxicities is not a requirement for administration of the second dose.

Instructions for Reconstitution

The drug product is light sensitive and must be protected from direct and indirect sunlight and unshielded fluorescent light during the preparation and administration of the infusion.

All preparation should take place in a laminar flow hood with the fluorescent light off. Prior to reconstitution, allow drug vials to come to room temperature. Reconstitute the contents of each vial with 5 mL Sterile Water for Injection, USP, using sterile syringes. Gently swirl each vial to mix. The final concentration of drug in the vial is 1 mg/mL. While in the vial, the reconstituted drug may be stored refrigerated (2-8C) for up to 8 hours.

Instructions for Dilution

Withdraw the desired volume from each vial and inject into a 100 mL IV bag of 0.9% Sodium Chloride Injection. Place the 100 mL IV bag into a UV protectant bag. The resulting drug solution in the IV bag will remain stable for up to 4 hours at room temperature.

Administration

DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS

Once the reconstituted [] is diluted into the IV bag containing normal saline, the resulting solution should be infused over a 2-hour period. The total time the drug is in the IV bag should not exceed 4 hours. A separate IV line equipped with a low protein-binding 1.2-micron terminal filter must be used for administration of the drug. [] may be given peripherally or through a central line. Premedication, consisting of acetaminophen and diphenhydramine, should be given before each infusion to reduce the incidence of a post-infusion symptom complex (see Adverse Reactions, Infusion-related events).

Special Populations: There were no observed relationships between patient demographics and the pharmacokinetic parameters. Possible effects of age, sex, weight, body surface area, and ethnic origin were examined. No observations suggested a change in dose for any patient population.^{11,12,13}

Elderly patients: No pharmacokinetic differences were seen when comparing patients ≤ 60 years of age and those ≥ 60 years of age. Therefore, dose modification in patients greater than 60 years of age is not required.^{11,12,13} There were considered to be no clinically important differences in TEAEs between the two age groups of patients.

Pediatric patients: Three children with AML received 6 mg/m^2 of gentuzumab zogamicin. Pharmacokinetic data are available for two of these children. Their pharmacokinetic parameters were C_{max} , 0.937 mg/L; AUC, 24.1 mg-h/L; $t_{1/2}$, 66.9 h; CL, 0.267 L/h (0.262 L/h/m^2); and V, 17.1 L (16.1 L/m^2).¹⁶

Hepatic or renal insufficiency: Patients with hepatic or renal impairment were not included in the clinical studies.

[

]

[

]